The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
Autoantibodies directed against phospholipids. These antibodies are characteristically found in patients with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; related autoimmune diseases, some non-autoimmune diseases, and also in healthy individuals.
A 44-kDa highly glycosylated plasma protein that binds phospholipids including CARDIOLIPIN; APOLIPOPROTEIN E RECEPTOR; membrane phospholipids, and other anionic phospholipid-containing moieties. It plays a role in coagulation and apoptotic processes. Formerly known as apolipoprotein H, it is an autoantigen in patients with ANTIPHOSPHOLIPID ANTIBODIES.
Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.
An antiphospholipid antibody found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including fetal death and spontaneous abortion, as well as a variety of hematologic and neurologic complications.
An acute or prolonged illness usually considered to be life-threatening or with the threat of serious residual disability. Treatment may be radical and is frequently costly.
Formation and development of a thrombus or blood clot in the blood vessel.
Acidic phospholipids composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. They occur primarily in mitochondrial inner membranes and in bacterial plasma membranes. They are the main antigenic components of the Wassermann-type antigen that is used in nontreponemal SYPHILIS SERODIAGNOSIS.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
A characteristic symptom complex.
Three or more consecutive spontaneous abortions.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
A systemic non-inflammatory arteriopathy primarily of middle-aged females characterized by the association of livedo reticularis, multiple thrombotic CEREBRAL INFARCTION; CORONARY DISEASE, and HYPERTENSION. Elevation of antiphospholipid antibody titers (see also ANTIPHOSPHOLIPID SYNDROME), cardiac valvulopathy, ISCHEMIC ATTACK, TRANSIENT; SEIZURES; DEMENTIA; and chronic ischemia of the extremities may also occur. Pathologic examination of affected arteries reveals non-inflammatory adventitial fibrosis, thrombosis, and changes in the media. (From Jablonski, Dictionary of Syndromes & Eponymic Diseases, 2d ed; Adams et al., Principles of Neurology, 6th ed, p861; Arch Neurol 1997 Jan;54(1):53-60)
Agents that prevent clotting.
The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
The formation or presence of a blood clot (THROMBUS) within a vein.
An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.
Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area.
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.
A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia.
Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference.
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.
Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.
A subnormal level of BLOOD PLATELETS.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
A condition characterized by neck stiffness, headache, and other symptoms suggestive of meningeal irritation, but without actual inflammation of the meninges (MENINGITIS). Spinal fluid pressure may be elevated but spinal fluid is normal. (DeJong, The Neurologic Examination, 4th ed, p673)
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
A condition that is caused by recurring atheroembolism in the lower extremities. It is characterized by cyanotic discoloration of the toes, usually the first, fourth, and fifth toes. Discoloration may extend to the lateral aspect of the foot. Despite the gangrene-like appearance, blue toes may respond to conservative therapy without amputation.
Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.
Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.
Central nervous system vasculitis that is associated with SYSTEMIC LUPUS ERYTHEMATOSUS. Clinical manifestations may include DEMENTIA; SEIZURES; CRANIAL NERVE DISEASES; HEMIPARESIS; BLINDNESS; DYSPHASIA; and other neurological disorders.
Reproduction of data in a new location or other destination, leaving the source data unchanged, although the physical form of the result may differ from that of the source.
A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain.
Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system.
Inflammation of a vein associated with a blood clot (THROMBUS).
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
A protein of the annexin family isolated from human PLACENTA and other tissues. It inhibits cytosolic PHOSPHOLIPASE A2, and displays anticoagulant activity.
Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to a serine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and serine and 2 moles of fatty acids.
Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.
Endogenous substances, usually proteins, that are involved in the blood coagulation process.
Antibodies produced by a single clone of cells.
Formation of an infarct, which is NECROSIS in tissue due to local ISCHEMIA resulting from obstruction of BLOOD CIRCULATION, most commonly by a THROMBUS or EMBOLUS.
Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.

Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. (1/684)

Antiphospholipid antibodies (aPL), anti-beta 2-glycoprotein I (anti-beta 2-GPI) and anti-oxidized-low-density lipoprotein (LDL) antibodies are all implicated in the pathogenesis of antiphospholipid syndrome. To investigate whether different autoantibodies or combinations thereof produced distinct effects related to their antigenic specificities, we examined the frequencies of antiphospholipid syndrome (APS)-related features in the presence of different antibodies [aPL, beta 2-GPI, anti-oxidized low density lipoprotein (LDL)] in 125 patients with APS. Median follow-up was 72 months: 58 patients were diagnosed as primary APS and 67 as APS plus systemic lupus erythematosus (SLE). Anticardiolipin antibodies (aCL), anti-beta 2-GPI and anti-oxidized LDL antibodies were determined by ELISA; lupus anticoagulant (LA) by standard coagulometric methods. Univariate analysis showed that patients positive for anti-beta 2-GPI had a higher risk of recurrent thrombotic events (OR = 3.64, 95% CI, p = 0.01) and pregnancy loss (OR = 2.99, 95% CI, p = 0.004). Patients positive for anti-oxidized LDL antibodies had a 2.24-fold increase in the risk of arterial thrombosis (2.24, 95% CI, p = 0.03) and lower risk of thrombocytopenia (OR = 0.41 95% CI, p = 0.04). Patients positive for aCL antibodies had a higher risk of pregnancy loss (OR = 4.62 95% CI, p = 0.001). When these data were tested by multivariate logistic regression, the association between anti-beta 2-GPI and pregnancy loss and the negative association between anti-oxidized LDL antibodies and thrombocytopenia disappeared.  (+info)

Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. (2/684)

OBJECTIVE: To determine any HLA associations with anti-beta2-glycoprotein I (anti-beta2GPI) antibodies in a large, retrospectively studied, multiethnic group of 262 patients with primary antiphospholipid antibody syndrome (APS), systemic lupus erythematosus (SLE), or another connective tissue disease. METHODS: Anti-beta2GPI antibodies were detected in sera using an enzyme-linked immunosorbent assay. HLA class II alleles (DRB1, DQA1, and DQB1) were determined by DNA oligotyping. RESULTS: The HLA-DQB1*0302 (DQ8) allele, typically carried on HLA-DR4 haplotypes, was associated with anti-beta2GPI when compared with both anti-beta2GPI-negative SLE patients and ethnically matched normal controls, especially in Mexican Americans and, to a lesser extent, in whites. Similarly, when ethnic groups were combined, HLA-DQB1*0302, as well as HLA-DQB1*03 alleles overall (DQB1*0301, *0302, and *0303), were strongly correlated with anti-beta2GPI antibodies. The HLA-DR6 (DR13) haplotype DRB1*1302; DQB1*0604/5 was also significantly increased, primarily in blacks. HLA-DR7 was not significantly increased in any of these 3 ethnic groups, and HLA-DR53 (DRB4*0101) was increased in Mexican Americans only. CONCLUSION: Certain HLA class II haplotypes genetically influence the expression of antibodies to beta2GPI, an important autoimmune response in the APS, but there are variations in HLA associations among different ethnic groups.  (+info)

Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. (3/684)

OBJECTIVE: To develop diagnostic criteria for a familial form of antiphospholipid antibody syndrome (APS), identify families with >1 affected member, examine possible modes of inheritance, and determine linkage to potential candidate genes. METHODS: Family members of probands with primary APS were analyzed for clinical and laboratory abnormalities associated with APS. Families with > or =2 affected members were analyzed by segregation analysis and typed for candidate genetic markers. RESULTS: Seven families were identified. Thirty of 101 family members met diagnostic criteria for APS. Segregation studies rejected both environmental and autosomal recessive models, and the data were best fit by either a dominant or codominant model. Linkage analysis showed independent segregation of APS and several candidate genes. CONCLUSION: Clinical and laboratory criteria are essential to identify the spectrum of disease associated with APS. We believe a set of criteria was developed that can precisely define affected family members with APS. Modeling studies utilizing these criteria strongly support a genetic basis for disease in families with APS and suggest that a susceptibility gene is inherited in an autosomal dominant pattern. However, in these families, APS was not linked with HLA, Fas, or other candidate genes, including beta2-glycoprotein 1, HLA, T cell receptor beta chain, Ig heavy chain, antithrombin III, Fas ligand, factor V, complement factor H, IgK, and Fas.  (+info)

The intrarenal vascular lesions associated with primary antiphospholipid syndrome. (4/684)

Even 10 yr after the identification of the antiphospholipid syndrome (APS), renal involvement in the course of APS is still relatively unrecognized, and is probably underestimated. The association of anticardiolipin antibodies and/or lupus anticoagulant with the development of a vaso-occlusive process involving numerous organs is now confirmed. In a multicenter study, 16 cases of "primary" APS (PAPS) were found and followed for 5 yr or more, all with renal biopsy. In all 16 cases of PAPS, there was a vascular nephropathy characterized by small vessel vaso-occlusive lesions associated with fibrous intimal hyperplasia of interlobular arteries (12 patients), recanalizing thrombi in arteries and arterioles (six patients), and focal cortical atrophy (10 patients). In combination, these led to progressive destruction of the kidney, accelerated by acute glomerular and arteriolar microangiopathy in five patients. Focal cortical atrophy is a distinctive lesion, present in 10 biopsies, and likely represents the histologic and functional renal analogue to the multiple cerebral infarcts detected on imaging studies. The clinical hallmark of this vascular nephropathy in PAPS is systemic hypertension, only variably associated with renal insufficiency, proteinuria, or hematuria. The ensemble of histologic renal lesions defined in this study should aid in the separation of the lesions found in cases of secondary APS, especially systemic lupus erythematosus, into those lesions related to APS and those related to the underlying disease.  (+info)

Mycoplasma penetrans bacteremia and primary antiphospholipid syndrome. (5/684)

Mycoplasma penetrans, a rare bacterium so far only found in HIV-infected persons, was isolated in the blood and throat of a non-HIV-infected patient with primary antiphospholipid syndrome (whose etiology and pathogenesis are unknown).  (+info)

Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion. (6/684)

We describe the case of a 39-year-old woman who suffered two iliofemoral venous thromboses, a cerebral ischemic infarct and recurrent fetal loss. Initial studies showed high levels of antiphospholipid antibodies (APAs) and a moderate thrombocytopenia. After her second miscarriage, laboratory diagnosis revealed that the woman was heterozygous for the factor V Leiden mutation and had a functional protein S deficiency as well as anti-protein S and anti-beta 2-glycoprotein I antibodies. The impairment of the protein C pathway at various points could well explain the recurrent thromboses in the patient and supports the role of a disturbed protein C system in the pathophysiology of thrombosis in patients with APAs.  (+info)

Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. (7/684)

The present study was designed to investigate the effects of immunoglobulin G obtained from patients with antiphospholipid syndrome (APS) on in-vitro models of trophoblast invasiveness and differentiation. We tested the binding of affinity-purified immunoglobulin G to human primary trophoblast cells. These antibodies affected the invasiveness and differentiation of cytotrophoblast cells after binding to the cell surface. In addition, we determined whether the drugs used to treat APS might be able to restore the trophoblast functions. Low-molecular weight heparin, in a dose-dependent manner, significantly reduced the immunoglobulin G binding to trophoblast cells and restored in-vitro placental invasiveness and differentiation. No effect was observed in the presence of acetylsalicylic acid. These observations may help in understanding the role of these treatments in women with APS.  (+info)

Flank ulcer in a patient with primary antiphospholipid syndrome. (8/684)

A 32-year-old woman had a recurrent shallow ulcer on the flank. A biopsy specimen showed thromboses in the dermal vessels and she was found to have circulating antiphospholipid antibody with no associated systemic disease. A clean ulcer developed on the flank of a patient with primary antiphospholipid syndrome is considered to be a rarely encountered/unusual presentation of this syndrome.  (+info)

Antiphospholipid antibodies occur in various clinical states, including the primary antiphospholipid syndrome. Clinical features in these conditions appear to be caused by vasculopathy associated with the presence of these antibodies.. We report the case of a patient with primary antiphospholipid syndrome who experienced cardiac necrosis secondary to myocardial microvasculopathy in the absence of vasculitis. This case demonstrates unequivocally that noninflammatory myocardial microvasculopathy occurs in the primary antiphospholipid syndrome per se without any clinical or immunologic signs of systemic lupus erythematosus or other disease process. The histopathologic findings in the skin and myocardial biopsies showed a noninflammatory vasculopathy characterized by bland thrombi and lack of infiltration of the vessel wall by inflammatory cells. Ultrastructural examination of the myocardial biopsy confirmed the vascular thrombosis and endothelial activation and showed no deposits in basement ...
Antiphospholipid antibody syndrome: Find the most comprehensive real-world symptom and treatment data on antiphospholipid antibody syndrome at PatientsLikeMe. 640 patients with antiphospholipid antibody syndrome experience fatigue, Pain, depressed mood, anxious mood, and insomnia and use Aspirin, Hydroxychloroquine, Warfarin, Enoxaparin, and Oxycodone to treat their antiphospholipid antibody syndrome and its symptoms.
OBJECTIVE To determine the prevalence of cardiac valvular involvement in patients with the primary antiphospholipid syndrome. DESIGN Cross-sectional study with evaluation of case patients and control patients by Doppler echocardiography. The mean follow-up for case patients was 22 months. SETTING University-based tertiary medical center. PATIENTS Twenty-eight consecutive patients who were diagnosed with the primary antiphospholipid syndrome during a 10-year period; 28 age- and sex-matched healthy controls. MEASUREMENTS AND MAIN RESULTS Ten patients (36%; 95% Cl, 19% to 56%) with the primary antiphospholipid syndrome had cardiac valvular involvement: Four patients had mitral valve involvement; four patients, aortic valve involvement; and two patients, both mitral and aortic valvular involvement; no patients had tricuspid or pulmonary valve disease. Eight of 10 patients had a regurgitant murmur. None of the control patients had valvular disease. The mean mitral valve thickness in patients with
Antiphospholipid syndrome is an autoimmune disease, in which antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes. Like many autoimmune diseases, it is more common in women than in men. The exact cause is not known, but activation of the system of coagulation is evident. Clinically important antiphospholipid antibodies (those that arise as a result of the autoimmune process) are associated with thrombosis and vascular disease. The syndrome can be divided into primary (no underlying disease state) and secondary (in association with an underlying disease state) forms. Anti-ApoH and a subset of anti-cardiolipin antibodies bind to ApoH, which in turn inhibits Protein C, a glycoprotein with regulatory function upon the common pathway of coagulation (by degradating activated factor V). Lupus anticoagulant (LAC) antibodies bind to prothrombin, thus increasing its cleavage to thrombin, its active ...
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
Systemic Antiphospholipid Syndrome, Antiphospholipid Syndrome information and help pages for APS patients, doctors and medical professionals Antiphospholipid Syndrome - Systemic Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory abnormalities. These include persistently elevated levels of antibodies directed against membrane anionic phospholipids (ie, anticardiolipin [aCL] antibody, antiphosphatidylserine) or their associated plasma proteins, predominantly beta-2 glycoprotein I (apolipoprotein H), or evidence of a circulating anticoagulant.Multiple terms exist for APS. Unfortunately, some synonyms can be confusing. Lupus anticoagulant (LA) syndrome, for example, is misleading because patients may not ... Antiphospholipid Syndrome - Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with typical laboratory
Donadini, MP, Crowther, M. Antiphospholipid syndrome: a challenging hypercoagulable state with systemic manifestations. Hematol-Oncol. vol. 24. 2010. pp. 669-76. (Recent concise review and update of this syndrome. Many of the clinical statistics were cited from this review.). Ruiz-Irastorza, G, Crowther, M, Branch, W, Khamashta, MA. Antiphospholipid syndrome. Lancet. vol. 376. 2010. pp. 1498-1509. (Along with the first listed reference, a key source for this chapter, especially with respect to treatment recommendations.). Frances, C. Dermatological manifestations of Hughes antiphospholipid antibody syndrome. Lupus. vol. 19. 2010. pp. 1071-77. (Current review of cutaneous manifestations.). Weinstein, S, Piette, W. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clinics N Am. vol. 22. 2008. pp. 67-77. (Relatively recent review of cutaneous findings.). Hughes, GRV. Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics. Lupus. vol. 19. 2010. pp. ...
How is Seronegative Antiphospholipid Antibody Syndrome abbreviated? SNAPS stands for Seronegative Antiphospholipid Antibody Syndrome. SNAPS is defined as Seronegative Antiphospholipid Antibody Syndrome rarely.
TY - JOUR. T1 - Bioprosthetic mitral valve thrombosis complicating antiphospholipid antibody syndrome, successfully treated with thrombolysis. AU - Chamsi-Pasha, Mohammed A.. AU - Alyousef, Tareq. AU - Sayyed, Samer H. PY - 2014/1/1. Y1 - 2014/1/1. N2 - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly limited. We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy. (Echocardiography 2014;31:E278-E281).. AB - The incidence of bioprosthetic valve thrombosis and related embolic complications is extremely rare, obviating the need for long-term anticoagulation. As a result, experience in the diagnosis and treatment of bioprosthetic valve thrombosis is fairly ...
Antiphospholipid antibody syndrome is a fascinatingly complex disorder. It is an autoimmune disease, whereby the immune system attacks our own tissues. This article summarises the basic mechanisms of the condition and main diseases it is involved in. Learn about the diverse effects antiphospholipid antibody syndrome (APS) can have, from heart attack to miscarriage and how APS can be treated.
TY - JOUR. T1 - De novo infantile primary antiphospholipid antibody syndrome. AU - Alshekaili, J.. AU - Reynolds, G.. AU - Cook, M. C.. PY - 2010/11. Y1 - 2010/11. N2 - Most autoimmune diseases are rare in infants. Early onset can represent an extreme phenotype arising from strong genetic predisposition relatively independent of environmental influence. Alternatively, neonatal autoimmunity can arise from transplacental passage of maternal pathogenic IgG autoantibodies. Distinguishing between these possible explanations is crucial for determining the prognosis in the specific patient, and has important implications for understanding pathogenesis. We report a case of neonatal thrombotic stroke associated with both cardiolipin and β2-glycoprotein I antibodies in neonatal serum but absent from cord blood and maternal serum. While the child also carried one prothrombotic allele of factor V (Leiden allele), which may have contributed to the risk of thromboembolic disease, the serological analysis ...
This guideline reviews the features of the Antiphospholipid syndrome [APS]- definition, clinical association, pathophysiology and the laboratory detection of Antiphospholipid antibodies. It includes a section on who should be tested for aPL antibodies and how this should influence their management. It also includes sections on the management of APS and the Catastrophic Antiphospholipid syndrome [CAPS].. ...
Antiphospholipid Antibody Syndrome (APS) is a highly prevalent cause of antibody-mediated thrombosis manifesting in venous thrombosis (DVT and PE), arterial thrombosis (most commonly stroke), and pregnancy complications. The diagnosis of definite APS requires both clinical and laboratory criterion as established by the working group of the International Congress on Antiphospholipid Antibodies (based on expert opinion). Since thrombosis and pregnancy loss are common in the general population, and antiphospholipid antibodies (aPL) occurs in a small percentage of the healthy public, it is important to demonstrate antibody persistence in patients who have the proper clinical indications in order to avoid misdiagnosis. Unfortunately, laboratory testing in this area lacks standardization, resulting in wide inter-laboratory variance. However, due to the commercialization of tests and automation, inter-laboratory variance has improved. Data on several new non-criterion tests suggest that they may ...
New life-saving treatments for Antiphospholipid syndrome in clinical trial on Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
TY - JOUR. T1 - Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome. T2 - Results of an international multicentre study. AU - Amengual, O.. AU - Forastiero, R.. AU - Sugiura-Ogasawara, M.. AU - Otomo, K.. AU - Oku, K.. AU - Favas, C.. AU - Delgado Alves, J.. AU - Žigon, P.. AU - Ambrožič, A.. AU - Tomšič, M.. AU - Ruiz-Arruza, I.. AU - Ruiz-Irastorza, G.. AU - Bertolaccini, M. L.. AU - Norman, G. L.. AU - Shums, Z.. AU - Arai, J.. AU - Murashima, A.. AU - Tebo, A. E.. AU - Gerosa, M.. AU - Meroni, P. L.. AU - Rodriguez-Pintó, I.. AU - Cervera, R.. AU - Swadzba, J.. AU - Musial, J.. AU - Atsumi, T.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - Objective A task force of scientists at the International Congress on Antiphospholipid Antibodies recognized that phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) might contribute to a better identification of antiphospholipid syndrome (APS). Accordingly, initial and ...
Rationale: Antiphospholipid syndrome (APS) in pregnancy may trigger the life-threatening catastrophic antiphospholipid syndrome (CAPS). Complement activation is implicated in the pathogenesis, and inhibition of complement factor C5 is suggested as an additional treatment option. Patient concerns, diagnosis and interventions: We present a pregnant patient treated with the C5-inhibitor eculizumab due to high risk of developing devastating APS-related complications. The complement inhibitory effects of the treatment were examined both in the patient and the premature infant. Outcomes: Complement activity in the mother recovered considerably faster than anticipated; however, no new thrombosis or CAPS developed during the last week of pregnancy or postpartum. Blood sampling from the umbilical vein and artery, and from the infant after delivery showed low complement activity; however, only 0.3% of the eculizumab concentration detected in the mother, consistent with low placental passage of eculizumab. ...
Sources Used in Current Review. Berg, T. (Updated 2015 April 15). Antiphospholipid syndrome and pregnancy. Medscape. Available online at http://emedicine.medscape.com/article/261691-overview. Accessed 2/15/2017.. (Reviewed 2016 March 21). Antiphospholipid syndrome. Lupus Foundation of America. Available online at http://www.lupus.org/answers/entry/antiphospholipid-syndrome. Accessed 2/15/2017.. Movva, S. (Updated 2016 July 1). Antiphospholipid syndrome workup. Medscape. Available online at http://emedicine.medscape.com/article/333221-workup. Accessed 2/15/2017.. Moake, J. (Revised 2016 September) Antiphospholipid antibody syndrome. Merck Manual Professional Version. Available online at http://www.merckmanuals.com/professional/hematology-and-oncology/thrombotic-disorders/antiphospholipid-antibody-syndrome-aps. Accessed 2/15/2017.. (Updated 2016 December). Antiphospholipid syndrome - APS. ARUP. Available online at http://www.arupconsult.com/Topics/APS.html?client_ID=LTD. Accessed 2/15/2017.. (© ...
TY - JOUR. T1 - IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. AU - Kelchtermans, H.. AU - Pelkmans, L.. AU - de Laat, B.. AU - Devreese, K. M.. PY - 2016/8. Y1 - 2016/8. KW - anti-cardiolipin. KW - anti-phospholipid antibody. KW - antiphospholipid syndrome. KW - (2)-glycoprotein I. KW - IgM. U2 - 10.1111/jth.13379. DO - 10.1111/jth.13379. M3 - Article. VL - 14. SP - 1530. EP - 1548. JO - Journal of Thrombosis and Haemostasis. JF - Journal of Thrombosis and Haemostasis. SN - 1538-7933. IS - 8. ER - ...
Discover Antiphospholipid Syndrome Awareness T-Shirt from antiphospholipid syndrome, a custom product made just for you by Teespring. With world-class production and customer support, your satisfaction is guaranteed.
The objective of this study was to highlight the need for investigation of antiphospholipid (aPL) antibodies in patients presenting with myocardial infarction (MI) and normal coronary arteries at angiography. We present five patients who were found to have had an MI without evidence of atherosclerosis. All had aPL antibodies and thus fulfilled the diagnosis of antiphospholipid syndrome (APS). Who did not have recurrent events on long-term anticoagulation maintaining an international normalised ratio of 3-4. This study suggests that APS is probably a major cause of MI in those with normal coronary arteries at angiography. It is an important diagnosis to make as they do not require anti-atherosclerotic treatment but appear, from this case series, to do well on high-dose warfarin. Further clinical studies are necessary to look at prevalence and best management in these patients.
TY - JOUR. T1 - Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia [9]. AU - Holtan, Shernan G.. AU - Knox, S. K.. AU - Tefferi, Ayalew. PY - 2006/7. Y1 - 2006/7. UR - http://www.scopus.com/inward/record.url?scp=33745225893&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=33745225893&partnerID=8YFLogxK. U2 - 10.1111/j.1538-7836.2006.01961.x. DO - 10.1111/j.1538-7836.2006.01961.x. M3 - Article. C2 - 16839370. AN - SCOPUS:33745225893. VL - 4. SP - 1632. EP - 1634. JO - Journal of Thrombosis and Haemostasis. JF - Journal of Thrombosis and Haemostasis. SN - 1538-7933. IS - 7. ER - ...
NorthShore encourages patients to utilize our medical library. Read our Antiphospholipid antibody syndrome encyclopedia resources online.
TY - JOUR. T1 - Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE). T2 - First report from the Italian Registry. AU - Barbui, T.. AU - Finazzi, G.. AU - Galli, M.. AU - Ciavarella, N.. AU - Schiavoni, M.. AU - Palareti, G.. AU - Marongiu, F.. AU - Muleo, G.. AU - Ferrari, L.. AU - Testa, S.. AU - Ballerini, G.. AU - Rossi Ferrini, P. L.. AU - Damasio, E.. AU - Trotta, A.. AU - Baudo, F.. AU - Pogliani, E.. AU - Rossi, E.. AU - DAngelo, A.. PY - 1993. Y1 - 1993. KW - antiphospholipid antibodies. KW - antiphospholipid syndrome. KW - Registry. KW - thrombocytopenia. KW - thrombosis. UR - http://www.scopus.com/inward/record.url?scp=0027515801&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0027515801&partnerID=8YFLogxK. M3 - Article. C2 - 8314161. AN - SCOPUS:0027515801. VL - 78. SP - 313. EP - 318. JO - Haematologica. JF - Haematologica. SN - 0390-6078. IS - 5. ER - ...
BACKGROUND Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by vascular thrombosis (arterial or venous) and/or pregnancy complications associated with the occurrence of autoantibodies, specifically lupus anticoagulant, anticardiolipin antibodies, and/or anti-β2 glycoprotein-I antibodies confirmed at least twice over a 12 week period according to the 2006 Sydney criteria. Antiphospholipid antibodies are encountered in the general population with a reported prevalence of 1% to 5% However, APS is far more infrequent with a prevalence of 40-50/100,000 persons and an incidence of about 5 new patients/100,000 persons. APS can be diagnosed in patients with no apparent clinical or laboratory pathology (primary APS) or it may be related to numerous other conditions, autoimmune diseases (usually systemic lupus erythematosus), malignancies, infections and drugs (secondary APS). Women are at risk for APS since the disease is encountered in both the primary and the secondary state
Pregnancy morbidity is one of the clinical manifestations used for classification criteria of antiphospholipid syndrome (APS). During the 14th International Congress on Antiphospholipid Antibodies (aPL), a Task Force with internationally-known experts was created to carry out a critical appraisal of …
Pathogenic and Therapeutic Role of Vitamin D in Antiphospholipid Syndrome Patients By Svetlana Jelic, Dejan Nikolic, Dragomir Marisavljević and Ljudmila Stojanovich Submitted: November 5th 2015Reviewed: August 2nd 2016 Published: April 26th 2017 DOI: 10.5772/65071 Abstract In this chapter, the novel findings on interrelationship between vitamin D status and two well‐known prothrombotic states, antiphospholipid syndrome, particularly its thrombotic phenotype, and metabolic syndrome will be reviewed. We shall present the results obtained from patients included in Serbian National Antiphospholipid Syndrome Registry, 68 patients with primary antiphospholipid syndrome (PAPS) and 69 patients with antiphospholipid syndrome associated with certain autoimmune rheumatic disease (sAPS), as well as 50 patients with pure metabolic syndrome (MetS). These results will be analysed and compared with the novel literature data. Prevalence of MetS in APS is high, with the atherogenic dyslipidaemia as its most ...
Antiphospholipid syndrome (APS) is characterized by thromboses in the larger arteries and veins and thrombotic microangiopathy. Indications: Suspicion of antiphospholipid syndrome. Thromboembolism in ...
HCQ may improve pregnancy outcomes for women with antiphospholipid syndrome July 2, 2015Treatment with hydroxychloroquine may reduce pregnancy risks and increase gestational duration in women with antiphospholipid syndrome, according to data presented at the European League Against Rheumatism Ann...
Schmeding and Schneider [57] reviewed the literature from 2000-2010 on the QOL of patients with SLE. It has been shown to lower QOL in patients with SLE vs. patients with other chronic diseases. SLE significantly reduces patients ability to cope with everyday activities. It is conditioned by age, fatigue and coexistence of neurological and psychiatric disorders, depression and irritability. There was no direct correlation between the degree of disease activity and organ damage in SLE and QOL.. Choi et al. [58] evaluated that the QOL of patients with SLE was lower than the control group, consisting healthy people. Reduced QOL resulted in depression, taking GCS and fatigue, which was not the result of the degree of disease activity and organ damage. Understanding psychological problems and appropriate treatment can help to improve the QOL of patients with SLE, especially those taking high doses of glucocorticosteroids, even if the disease activity is low. The study included 108 patients with SLE, ...
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature as well as obstetrical complications. The pathophysiological hallmark is thrombosis, but other factors such as complement activation might be important. Prevention of thrombotic manifestations associated with APS includes lifestyle changes and, in individuals at high risk, low-dose aspirin. Prevention and treatment of thrombotic events are dependent mainly on the use of vitamin K antagonists. Immunosuppression and anticomplement therapy have been used anecdotally but have not been adequately tested. Pregnancy morbidity includes unexplained recurrent early miscarriage, fetal death and late obstetrical manifestation such as pre-eclampsia, premature birth or fetal ...
During the past 12 years both clinicians and researchers involved in rheumatology, haematology, clinical immunology, and gynaecology have been inundated with hundreds of manuscripts regarding the so called antiphospholipid syndrome (APS).. As a result of the spread of information about the pathogenesis and clinical aspect of antiphospholipid antibodies (APA) in humans, non-professional APA readers have been often puzzled by APA characterisation, criteria for APS definition, reliability of assays for APA detection, and APS management.. None the less, thanks to the growing number of clinical findings concerning APS, it has became apparent that understanding of this syndrome may be of interest to other medical specialties.. Asherson and colleagues faced the difficult task of going through the great amount of information on APS and to present it in a systematic and didactic way.. The book is homogeneously structured in three sections dealing with aetiopathogenic mechanisms of APS (section I), its ...
Antiphospholipid syndrome is a systemic autoimmune disorder. It is usually defined as the clinical complex of vascular occlusion and ischemic events occurring in patients who have circulating antiphospholipid antibodies. Clinical presentation A...
Antiphospholipid syndrome is a systemic autoimmune disorder. It is usually defined as the clinical complex of vascular occlusion and ischaemic events occurring in patients who have circulating antiphospholipid antibodies. Pathology Patients hav...
Outcome of primary antiphospholipid syndrome in childhood. Gattorno, M.; Falcini, F.; Ravelli, A.; Zulian, F.; Buoncompagni, A.; Martini, G.; Resti, M.; Picco, P.; Martini, A. // Lupus;2003, Vol. 12 Issue 6, p449 The objective of this paper is to investigate the long-term outcome of primary antiphospholipid syndrome (APS) in the paediatric age. The features of unselected patients with primary APS who had disease onset before the age of 16 years were retrospectively analysed in three Italian referral... ...
The classical clinical picture of the antiphospholipid syndrome (APS) is characterized by venous and arterial thromboses, fetal losses and thrombocytopenia, in the presence of antiphospholipid...
A 32-year-old woman was admitted for mild gait difficulty and behavioural changes of 3 years duration. Familial and medical histories were unremarkable. Neurological examination revealed: mildly slowed gait, decreased synkinesias of the left arm (held abducted and flexed), increased deep tendon reflexes, Babinski signs, mild lower limb spasticity and dysmetria of left limbs. Depression and mild executive dysfunctions were also found.. Brain CT showed cerebral white matter (WM) calcifications (fig 1). MRI revealed T2 WM hyperintensities in the centra semiovalia, around the frontal horns and, to a lesser extent, in the posterior regions. Post-contrast MRI demonstrated points and stripes of enhancement in the periventricular WM, which are consistent with engorged medullary vessels (fig 2). Proton ...
Fingerprint Dive into the research topics of Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Together they form a unique fingerprint. ...
Find and save ideas about Lupus anticoagulant on Pinterest. | See more ideas about Antiphospholipid syndrome, Lupus antibodies and Lupus facts.
Blood. 117(25), 6939-6947. Agar C, de Groot PG, Marquart JA & Meijers JCM. (2011b) Evolutionary conservation of the LPS binding site of beta2-glycoprotein I. Thromb Haemost. In press. Arad A, Proulle V, Furie RA, Furie BC & Furie B. (2011) β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 117(12), 3453-3459. Bevers EM & Galli M. (1990) Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin. Electron microscopy analysis of β2GPI. , 2010). Analysis of EM pictures showed that more than 99% of plasma β2GPI was in a closed conformation. These observations suggested that plasma β2GPI circulates in a circular (closed) conformation, whereas after interaction with antibodies β2GPI undergoes a major conformational change into a fishhook-like (open) structure. , 1996). When antibodies toward β2GPI were added to plasma, clotting times prolonged in a β2GPI-dependent ...
The antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPA) associated with thrombosis (arterial and venous) and pregnancy morbidity. This thesis has aimed to investigate the frequency of protein C pathway defects in patients with aPA and to study clinical correlates examine the mechanisms of antiphospholipid interference in the protein C pathway and to assess activated protein C (APC) resistance in patients with aPA in terms of thrombin generation. Although have I have discovered a high degree of heterogeneity in the phenotype of patients with APS, I have demonstrated APC resistance and increased thrombin generation in the majority of patients with APS. While in some cases, APC resistance is clearly immunoglobulin mediated, it is a multifactorial phenomenon with many confounding variables. My data suggest that immunoglobulin dependent APC resistance may occur through P2 glycoprotein-I dependent and independent mechanisms. In a detailed study of ...
Erkan: Antiphospholipid Syndrome patients with vascular events generally receive life-long anticoagulation, despite the lack of high-quality data on the risk of recurrence and optimal duration of anticoagulation. Given that at least 50% of thrombotic events in aPL-positive patients have recognizable triggers, the possibility of discontinuing anticoagulation in highly selected patients exists, especially when the triggers are eliminated. However, discontinuation of anticoagulation is a critical decision that requires careful assessment of comorbidities, triggers, and residual thrombosis as well as patient education. The 13th International Congress on aPL Treatment Task Force recommended that in cases of first venous event, low-risk aPL profile, and a known transient precipitating factor, anticoagulation could be limited to 3-6 months. Given the importance of this question, i.e., anticoagulation withdrawal in APS, the development of a multicenter clinical trial protocol to determine whether ...
A look at antiphospholipid antibody syndrome, what laboratory tests can support the diagnosis of this syndrome, what are the causes and how is it treated. ...
This case may be coincidental or it may be that the plasminogen deficiency increased the thrombotic tendency of APS in this patient. , 1996). Biochemistry. 35(43), 1383313842. 3 Genetics of Antiphospholipid Syndrome Jesús Castro-Marrero, Eva Balada, Josep Ordi-Ros and Miquel Vilardell-Tarrés Systemic Autoimmune Diseases Research Unit, Vall dHebron University Hospital Research Institute Universitat Autónoma de Barcelona, Barcelona Spain 1. , 2006). The etiology of APS, however, is still unknown. pdf in Orphanet, INSERM MIM nº 107320). APS can involve almost any organ system, including a wide range of clinical manifestations. , 2008). 2011) Microparticles in hemostasis and thrombosis. Circ Res. 108(10), 1284-1297. Pangburn MK & Rawal N. (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans. 30(Pt 6), 1006-1010. Pennings MT, van Lummel M, Derksen RH, Urbanus RT, Romijn RA, Lenting PJ & de Groot PG. (2006) Interaction of beta2-glycoprotein I with members of the ...
Antiphospholipid syndrome - also known as Hughes syndrome - is an autoimmune disorder in which the immune system attacks phospholipids.
Fatma Demir Yenig rb z, Hale ren. Pediatric Deep Venous Thrombosis and Pulmonary Embolism: Can It Be Antiphospholipid Syndrome?. Turk J Hematol. 2019; 36(3): 205- ...
Abstract. The antiphospholipid syndrome is an antibody-mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events. Seve
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x Esteve-Valverde E, Ferrer-Oliveras R, Alijotas-Reig J. Obstetric antiphospholipid syndrome. Rev Clin Esp. 2016;216:135-45. https://doi.org/10.1016/j.rce.2015.09.003 Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramon E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011-8. https://doi.org/10.1136/annrheumdis-2013-204838 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol. 2011;7:330-9. https://doi.org/10.1038/nrrheum.2011.52 Chighizola CB, Raschi E, Borghi MO, Meroni PL. Update on the pathogenesis and ...
Ann Arbor, MI - For men and women affected with antiphospholipid syndrome (APS), blood thinners are the main treatment option. Unfortunately, treatment with blood thinners does not prevent all cases of blood clotting in APS, says Dr. Jason Knight, an assistant professor of rheumatology at Michigan Medicine. APS is an autoimmune condition characterized by blood clots…
TY - JOUR. T1 - Efficacy of eculizumab in a patient with immunoadsorption- dependent catastrophic antiphospholipid syndrome. T2 - A case report. AU - Kronbichler, Andreas. AU - Frank, Renate. AU - Kirschfink, Michael. AU - Szilágyi, Ágnes. AU - Csuka, Dorottya. AU - Prohászka, Z.. AU - Schratzberger, Peter. AU - Lhotta, Karl. AU - Mayer, Gert. PY - 2014/11/14. Y1 - 2014/11/14. N2 - Catastrophic antiphospholipid syndrome (CAPS) is a rare but devastating complication in patients with antiphospholipid syndrome (APS) with a high morbidity and mortality. We describe a case of a 30-year old female patient with immunoglobulin A (IgA) deficiency who underwent splenectomy because of idiopathic thrombocytopenic thrombocytopenia. Subsequently, an APS and finally systemic lupus erythematosus was diagnosed. After an uncomplicated pregnancy that was terminated by cesarean section, the patient developed severe CAPS with cerebral, myocardial, renal, and pulmonary involvement. Because of IgA deficiency, ...
Introduction: Catastrophic Antiphospholipid syndrome (CAPS) and heparin-induced thrombocytopenia (HIT) are immune- mediated thrombotic conditions caused by an...
Catastrophic Antiphospholipid Antibody Syndrome (CAPS) is a rare condition in which life-threatening blood clots form in multiple organs simultaneously and can lead to multi-organ system failure and death. The causes of CAPS are not entirely understood, but CAPS episodes are often triggered by stressful events such as infections, surgery, or trauma. For patients who survive an episode of CAPS, permanent kidney failure is not uncommon because the kidneys are the organ system most frequently affected in CAPS. Kidney transplantation is the treatment of choice for end-stage kidney disease, but patients with a history of CAPS are exceptionally high-risk kidney transplant recipients because the chance that surgery itself could trigger a life-threatening or transplant-threatening episode of CAPS is significant. As a result, patients with CAPS are not generally considered candidates for transplantation. Despite this, these patients have a severely decreased life-expectancy on dialysis and their ...
Catastrophic Antiphospholipid Antibody Syndrome (CAPS) is a rare condition in which life-threatening blood clots form in multiple organs simultaneously and can lead to multi-organ system failure and death. The causes of CAPS are not entirely understood, but CAPS episodes are often triggered by stressful events such as infections, surgery, or trauma. For patients who survive an episode of CAPS, permanent kidney failure is not uncommon because the kidneys are the organ system most frequently affected in CAPS. Kidney transplantation is the treatment of choice for end-stage kidney disease, but patients with a history of CAPS are exceptionally high-risk kidney transplant recipients because the chance that surgery itself could trigger a life-threatening or transplant-threatening episode of CAPS is significant. As a result, patients with CAPS are not generally considered candidates for transplantation. Despite this, these patients have a severely decreased life-expectancy on dialysis and their ...
Looking for online definition of antiphospholipid-antibody syndrome in the Medical Dictionary? antiphospholipid-antibody syndrome explanation free. What is antiphospholipid-antibody syndrome? Meaning of antiphospholipid-antibody syndrome medical term. What does antiphospholipid-antibody syndrome mean?
Mycoplasma penetrans, a rare bacterium so far only found in HIV-infected persons, was isolated in the blood and throat of a non-HIV-infected patient with primary antiphospholipid syndrome (whose etiology and pathogenesis are unknown).
Sixty six per cent of patients who survive an initial catastrophic APS event remained symptom free with anticoagulation during an average follow up of 67.2 months. Twenty six per cent of the survivors developed further APS related events and the mortality rate of these patients was about 25%.. Doctors have been increasingly recognising catastrophic APS but still many unresolved questions exist. The optimal treatment combination at the time of a catastrophic APS event is controversial,6 but anticoagulation is the preferred treatment in the long term. Although short term outcomes of catastrophic APS are documented in two different series,3,4 the long term outcomes are unknown. This is the first study demonstrating that catastrophic APS recurrence is unusual and patients treated with anticoagulation generally have a stable course.. Long term anticoagulation with warfarin is the standard of care to prevent a recurrent vascular event in patients with APS. The recurrence rate in untreated patients is ...
TY - JOUR. T1 - Antiphospholipid antibodies and retinal vascular disease. AU - Dunn, James P.. AU - Noorily, S. W.. AU - Petri, M.. AU - Finkelstein, D.. AU - Rosenbaum, J. T.. AU - Jabs, D. A.. PY - 1996. Y1 - 1996. N2 - Background. Antiphospholipid antibody retinopathy is a rare and poorly defined clinical entity in which the proper diagnosis has important ocular and systemic implications. The clinical course of five patients with antiphospholipid antibody retinopathy is described and the role of such antibodies in idiopathic retinal venous occlusive disease is investigated. Methods. Five case reports are presented highlighting the presentation, course, therapy, associations and outcomes of patients with antiphospholipid antibody retinopathy. In addition, twenty additional patients presenting with idiopathic retinal venous occlusive disease were tested for the presence of antiphospholipid antibodies. Results. All five patients with antiphospholipid antibody retinopathy had diffuse retinal ...
A 27-year-old Hispanic female was admitted to hospital with fever, a sudden marked decrease in vision, and multi-organ failure shortly after preterm delivery by cesarean section for eclampsia. Her past history was significant for a spontaneous first
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
This page includes the following topics and synonyms: Antiphospholipid Antibody Test, aPL Antibody, Antiphospholipid Antibodies, Antiphospholipid Antibody, Anticardiolipin Antibody Test, Anticardiolipin Antibody.
Hepatitis C, a worldwide viral infection, is an important health problem in Brazil. The virus causes chronic infection, provoking B lymphocyte dysfunction, as represented by cryoglobulinemia, non-organ-specific autoantibody production, and non-Hodgkins lymphoma. The aim of this research was to screen for the presence of antiphospholipid autoantibodies in 109 Brazilian hepatitis C virus carriers without clinical history of antiphospholipid syndrome. Forty healthy individuals were used as the control group. IgA, IgG, and IgM antibodies against cardiolipin and β2-glycoprotein I were measured with an enzyme-linked immunosorbent assay, using a cut-off point of either 20 UPL or 20 SBU. While 24 (22.0%) hepatitis C carriers had moderate titers of IgM anticardiolipin antibodies (median, 22.5 MPL; 95%CI: 21.5-25.4 MPL), only three carriers (,3%) had IgG anticardiolipin antibodies (median, 23 GPL; 95%CI: 20.5-25.5 GPL). Furthermore, IgA anticardiolipin antibodies were not detected in these individuals. ...
You may also need to take blood thinners for 3 to 4 weeks after surgery to lower your risk of blood clots.. ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS) In general, you will need long-term treatment with a blood thinner for a long time if you have the APS. Initial treatment may be heparin, either unfractionated or low-molecular heparin. These medicines are given by injection.. In most cases, warfarin (Coumadin), which is given by mouth, is then started. It is necessary to monitor the level of anticoagulation frequently. This is most often done using the INR test.. If you have APS and become pregnant, you will need to be followed closely by a provider expert in this condition. You will not take warfarin during pregnancy, but will be given low-molecular weight heparin instead.. If you have SLE and APS your provider will also recommend that you take hydroxychloroquine. ...
Antiphospholipid syndrome is a thrombotic disorder characterized by the association of arterial and venous thrombosis with the antibodies directed toward phospholipids. The presence of these antibodies in systemic lupus erythematosus(SLE) has been shown to be related to several clinical and analytical alterations. We experienced one case of lupus nephritis with positive antiphospholipid antibodies in a 10-year-old girl whose chief complaint was persistent microscopic hematuria. We report this case with a brief review of related literatures. (J. Korean Soc Pediatr Nephrol 2001 ;5 : 219-24) ...
TY - JOUR. T1 - Antiphospholipid antibodies and fetal loss. T2 - Clinical association and possible pathogenetic role in experimental models. AU - Meroni, P. L.. AU - Piona, A.. AU - La Rosa, L.. AU - Tincani, A.. AU - Balestrieri, G.. AU - Casali, P.. PY - 1995/1/1. Y1 - 1995/1/1. N2 - It is widely accepted that the persistent presence of antiphospholipid antibodies (aPL) represents a high risk factor for recurrent spontaneous abortion, fetal growth retardation, and complicated pregnancies (early and severe preeclampsia). However, whether aPL can be regarded as direct pathogenetic antibodies and which pathogenetic mechanism sustains the clinical manifestations are still open questions. We approached the problem by (a) setting up an experimental model of fatal loss in naive mice; and (b) by investigating the deposition of β2 glycoprotein I (β2 GPI)-the plasma cofactor for aPL-on placentae from women suffering from aPL-associated recurrent abortion. In the experimental model we found that ...
TY - JOUR. T1 - Restricted T-cell receptor β-chain usage by T cells autoreactive to β2-glycoprotein I in patients with antiphospholipid syndrome. AU - Yoshida, Kazue. AU - Arai, Takahide. AU - Kaburaki, Junichi. AU - Ikeda, Yasuo. AU - Kawakami, Yutaka. AU - Kuwana, Masataka. PY - 2002/4/1. Y1 - 2002/4/1. N2 - We recently identified CD4+ T cells that are autoreactive to β2-glycoprotein I (β2GPI) and that promote antiphospholipid antibody production in patients with antiphospholipid syndrome (APS). In this study, T-cell receptor (TCR) β chains of β2GPI-reactive T cells were examined in 8 β2GPI-responders, including 5 patients with APS and 3 healthy subjects, using polymerase chain reaction and single-strand conformation polymorphism (PCRSSCP) analysis combined with in vitro stimulation of peripheral blood T cells with recombinant β2GPI. The TCR Vβ segments that expanded oligoclonally after stimulation with β2GPI varied among responders, but the Vβ7 and Vβ8 segments were commonly ...
TY - JOUR. T1 - Comparative analysis of different enzyme immunoassays for assessment of phosphatidylserine-dependent antiprothrombin antibodies. AU - Amengual, Olga. AU - Horita, Tetsuya. AU - Binder, Walter. AU - Norman, Gary L.. AU - Shums, Zakera. AU - Kato, Masaru. AU - Otomo, Kotaro. AU - Fujieda, Yuichiro. AU - Oku, Kenji. AU - Bohgaki, Toshiyuki. AU - Yasuda, Shinsuke. AU - Atsumi, Tatsuya. PY - 2014/9. Y1 - 2014/9. N2 - Phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) were strongly correlated with the presence of lupus anticoagulant showing a high specificity for the diagnosis of antiphospholipid syndrome. However, the main criticism for the clinical applicability of aPS/PT testing is the lack of reproducibility of the results among laboratories. In this study, we measured IgG and IgM aPS/PT using our original in-house enzyme-linked immunosorbent assays (ELISA) and commercial ELISA kits to assess the assay performance and to evaluate the accuracy of aPS/PT results. The ...
Of the several types of antiphospholipid antibodies (aPL) described, lupus anticoagulant (LA) antibodies and anticardiolipin antibodies (aCL) are the types most clearly associated with antiphospholipid antibody syndrome (APS), the latter being the focus of this chapter. The Venereal Disease Research Laboratory (VDRL) and rapid plasma reagin tests were then developed, both employing purified cardiolipin combined with cholesterol and lecithin as the antigen. Classification of patients with APS considers both clinical and laboratory criteria. The syndrome is classified as primary APS when not associated with another disease and accounts for over 50% of cases. The first category of aPL, LA antibodies, are detected with certain phospholipid-dependent coagulation assays. Definite APS is present when at least one clinical criterion and one laboratory criterion are present. LAs are antibodies that are prothrombotic in vivo but display anticoagulant properties in vitro (i.e., they prolong certain coagulation
The objective of the study is to analyze the efficacy and safety of splenectomy in the management of refractory autoimmune thrombocytopenia (AT)/autoimmune hemolytic anemia (AIHA) associated or not with systemic lupus erythematosus. Thirty-four patients after splenectomy due to severe AT and/or AIHA were divided into group 1 (G1) 18 SLE/APS patients: 9 AT/SLE patients, 6 SLE/antiphospholipid syndrome (APS), and 3 primary APS. Group 2 (G2): 16 patients without SLE/APS: 2 Fisher-Evans syndrome and 14 AIHA. Surgery approach when (1) platelets ≤ 50,000/ml despite 2 weeks on medical therapy, (2) medically dependent, and (3) medically intolerant or after two hemolytic crises in AIHA patients ...
Myasthenia is a rare neurological condition with risk of death in case of inappropriate management. The outcome of this pathology is very bad in developing countries with inadequate technical Platform. We underlined the main difficulties of diagnostic and the management of Myasthenie and antisynthetase antibody syndrome in a 44 years-old Togolese man.
Summary Antiphospholipid antibodies (APLA) have been shown to activate endothelial cells (EC) in vitro, as documented by an increased expression of tissue factor as well as leukocyte adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule (VCAM)-1 and E-selecti...
Read Antiphospholipid antibodies increase the levels of mitochondrial DNA in placental extracellular vesicles: Alarmin-g for preeclampsia, Scientific Reports on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Our data suggest that subsequent thrombo-occlusive events and death after focal cerebral ischemia may occur sooner and more frequently in patients found to have IgG aCL immunoreactivity ,40 GPL units at the time of their index focal cerebral ischemic event when compared with patients who harbor 10 to 40 GPL at the time of their index event. Therefore GPL ,40 may be an important prognostic marker for subsequent thrombo-occlusive events in patients with index focal cerebral ischemia. Patients with ,40 GPL also appear to have more features of the antiphospholipid syndrome: younger age at onset and more recurrent strokes at the time of diagnosis.21 Furthermore, being in the GPL ,40 group appears to confer a sixfold-increased risk of developing subsequent TIAs only compared with being in the GPL ≤40 group. TIAs do not generally have as equally bad an outcome as ischemic stroke, although many hemispheric TIAs are minor infarcts by persistent subtle signs or neuroimaging abnormalities, and cognitive ...
Renal vein thrombosis (RVT) is the formation of a clot in the vein that drains blood from the kidneys, ultimately leading to a reduction in the drainage of one or both kidneys and the possible migration of the clot to other parts of the body. First described by German pathologist Friedrich Daniel von Recklinghausen in 1861, RVT most commonly affects two subpopulations: newly born infants with blood clotting abnormalities or dehydration and adults with nephrotic syndrome. Nephrotic syndrome, a kidney disorder, causes excessive loss of protein in the urine, hypoalbuminemia, hypercholesterolemia and edema, triggering a hypercoagulable state and increasing chances of clot formation. Other less common causes include hypercoagulable state, cancer, renal transplantation, behcet syndrome, antiphospholipid antibody syndrome or blunt trauma to the back or abdomen. Treatment of RVT mainly focuses on preventing further blood clots in the kidneys and maintaining stable renal function. The use of ...
Antiphospholipid antibodies (APAs) are detected in various autoimmune diseases, such as antiphospholipid syndrome (APS) and systemic lupus erythematosus. In addition to their binding to negatively charged phospholipids, APAs often cross-react with other molecules. Their potential biological effects are not fully understood. Apoptotic cells are a potential source of auto-antigens during systemic autoimmunity. Inefficient clearance of apoptotic cells results in the development of autoimmune manifestations and intracellular antigens such as nucleosomes become accessible during apoptosis. We examined a panel of monoclonal APAs generated from NZW/BXSB F1, a strain which spontaneously develops autoimmune symptoms reminiscent of APS. These APAs did not bind to live cells, but reacted strongly with different structures within apoptotic cells. Further analysis with various inhibitors indicated that the binding of APAs to apoptotic cells depends on specific caspase activities and on the modification of ...
Systemic lupus erythematosus (SLE) is an autoimmune disorder that occurs mainly in young women and can affect multiple organ systems. The clinical course of SLE is often one of spontaneous remissions and relapses. One of the most feared complications of SLE is acute neuropsychiatric disorders because of the profound effect on the patient and the association with high mortality (1). These disorders can present as seizures, psychosis, organic brain syndrome, strokes, and transient ischemic attacks (TIA) and may result in cumulative neurocognitive dysfunction. Recognized potential causes of these syndromes include cerebritis and hypercoagulable states such as antiphospholipid antibody syndrome and vasculitis (2). SLE is also known to promote the premature development of atherosclerosis, which is a common cause of stroke/TIA and dementia (3). Recently, attention has focused on the cardiac valvular abnormalities seen in SLE and their potential role in acute neuropsychiatric syndromes (4-7). The paper ...
Burgundy Awareness Ribbon Meaning What causes are associated with the burgundy awareness ribbon? * Amyloidosis * Antiphospholipid Antibody Syndrome * Aortic Aneurysm * AV Malformation * Brain Aneurysm * Congenital Vascular Cavernous Malformation * Cystic Hygroma * Disabled Adults * Factor V Leiden * Headache * Hemangioma * Hemiplegic Migraine * Hemochromatosis * Hirschsprungs Disease * Hughes Syndrome * Meningitis * Multiple Myeloma * Parkes Weber Syndrome * Port-Wine Stain Birthmark
An interdisciplinary faculty of neurologists and rheumatologists will provide an update on neuro-rheumatology-the neurological manifestations of systemic inflammatory and autoimmune syndromes. Part I of this course will review rheumatological diagnosis, physical examination techniques, and interpretation of laboratory studies; discuss neurological manifestations and treatment of Systemic Lupus Erythematosus, Sjogrens Syndrome, Antiphospholipid Antibody Syndrome, Mixed Connective Tissue Disease, and Rheumatoid Arthritis; and review CNS Vasculitis and other vasculitides. Part II will review diagnosis and treatment of Neurosarcoidosis, Pachymeningitis and Behcets Disease; discuss Peripheral Nervous System Manifestations of Rheumatological Diseases; and conclude with an interdisciplinary case discussion with faculty highlighting how rheumatologists and neurologists approach differential diagnosis, treatment, and management. This program complements C78: Neuro-rheumatology: Neurological ...
The antiphospholipid syndrome (APS) is a prothrombotic state characterized by recurrent arterial and venous thrombosis, recurrent pregnancy loss, and the presence of circulating antiphospholipid antibodies (aPL). Thrombophilia may be associated with premature atherosclerosis, and accelerated atherosclerosis was suggested as an additional clinical feature of APS. This pathological process may be mediated by the direct proinflammatory and procoagulant activity that aPLs exert on endothelial cells or indirectly, via the inflammatory/immune mechanisms that have been implicated in autoantibody-mediated thrombosis.40,41 In 1993, Vaarala et al42 provided the first evidence that aPLs may be involved in atherosclerosis. This study also suggested that some aPLs were capable of cross-reacting with oxLDL in SLE. Hypercholesterolemia, diabetes mellitus, smoking, obesity, arterial hypertension, and sedentary lifestyle in APS appear to be similar to those in the general population.41 Therefore, the ...
Antibodies directed toward phosphatidylethanolamine (anti-PE) appear to occur particularly frequently in women with unexplained early fetal loss (UFL). Two studies have shown that the presence of anti-PE antibodies is a higher independent risk factor for early UFL than either aCL or anti-β2GPI antibodies.22,23 Moreover, anti-PE antibodies have been reported as the only aPL antibodies found in cases of UFL (73%). Regarding thrombosis, which is the other main clinical feature of APS, a multicenter study conducted within the framework of the European Forum on aPL antibodies found the prevalence of anti-PE was 15% in patients with unexplained venous thrombosis; this specificity was found mainly as the sole aPL antibody.24 At present, there is no accepted standardized method for the measurement of anti-PE, and the heterogeneity of these antibodies increases the difficulties in attaining such a goal. This problem significantly limits the utility of this assay. Hence, following current evidence, the ...
The objective of the study is to analyze the efficacy and safety of splenectomy in the management of refractory autoimmune thrombocytopenia (AT)/autoimmune hemolytic anemia (AIHA) associated or not with systemic lupus erythematosus. Thirty-four patients after splenectomy due to severe AT and/or AIHA were divided into group 1 (G1) 18 SLE/APS patients: 9 AT/SLE patients, 6 SLE/antiphospholipid syndrome (APS), and 3 primary APS. Group 2 (G2): 16 patients without SLE/APS: 2 Fisher-Evans syndrome and 14 AIHA. Surgery approach when (1) platelets ≤ 50,000/ml despite 2 weeks on medical therapy, (2) medically dependent, and (3) medically intolerant or after two hemolytic crises in AIHA patients ...
If a woman suffers from autoimmune disease (AD), several factors can affect pregnancy or neonatal outcome: repeated spontaneous pregnancy losses (frequently related to antiphospholipid antibodies (aPL)), neonatal lupus with complete congenital heart block (CHB) (linked to transplacental passage of IgG anti Ro/SS-A antibodies) and the disease activity itself that can affect the mother, the pregnancy and fetal outcome. If appropriately managed, the antiphospholipid syndrome (APS) is bone of the few tractable causes of pregnancy losses.Q A recent case control study, on babies from APS-mothers and healthy mothers, did not show any difference in the occurrence of neonatal complications. There are few data about the longterm outcome of babies born to patients with AD. We recently reported increased occurrence of learning disabilities in children born to aPL positive mothers with systemic lupus erythematosus (SLE). The modern management of pregnancy in patients with AD includes the treatment of disease ...
Patients with renal diseases are prone to both thrombosis and bleeding, as they have profound changes in all three classic components of coagulation, defined approximately 150 years ago by Virchow: blood flow, vessel wall (endothelial injury), and coagulation properties of the blood (e.g., coagulation and fibrinolytic systems and platelets). The prothrombotic state in chronic kidney disease (CKD), glomerular diseases (including systemic lupus and vasculitis), and some less frequent conditions (idiopathic retroperitoneal fibrosis, antiphospholipid syndrome, hemolytic‐uremic syndrome, etc.) is associated with vascular endothelial damage, increase in certain coagulation and antifibrinolytic factors, decrease in anticoagulation proteins, dyslipidemia, hypoalbuminemia, changes in platelet membranes, hemo‐ and peritoneal dialysis and heparin treatment, increased microRNAs and circulating microparticles, antiphospholipid antibodies, nephrotic syndrome, anemia with high platelet count, and so on.
Results At least one EE was detected in 118 (63%) patients (52 cerebral, 95 other locations) after IE diagnosis in 80 (time interval between IE and EE diagnosis: 5.9±11.3 days). At least one aPL antibody was found in 31 patients (17%).. Detection of EE over time after IE diagnosis was more frequent among patients with anti-β2GPI IgM (log-rank P=0.0036) and that of cerebral embolisms, among patients with aCL IgM and anti-β2GPI IgM (log-rank P=0.002 and P,0.0001, respectively).. Factors predictive of EE were anti-β2GPI IgM (HR=3.45 (1.47-8.08), P=0.0045), creatinine (2.74 (1.55-4.84), P=0.0005) and vegetation size (2.41 (1.41-4.12), P=0.0014). Those of cerebral embolism were aCL IgM (2.84 (1.22-6.62), P=0.016) and anti-β2GPI IgM (4.77 (1.79-12.74), P=0.0018). ...
We report in Figure 2 the annual rate (∼ 0.4%) of first cardiovascular event (including VTE) in normal white population at 35 to 55 years of age,14 that (1.36%) of 125 single aPL positive carriers with a mean age of 41 years (data taken by a recently published study by our group),15 and that (5.3%) of triple-positive carriers of this study (mean age, 45 years). Annual rate in a cohort of SLE patients half of whom had aPL was 2.9 per 100 patient-years.16 Hence, because less than half of our cohort had autoimmune disorders, the higher incidence of TEs recorded in this study may be related to the selection of high-risk aPL-positive population. Likewise, in patients with APS and triple positivity,7 TEs were equally distributed among arterial and venous circulation. Some patients in this study were treated with aspirin for primary thromboprophylaxis, behavior that did not lead to a significant reduction of events. To our knowledge, only one prospective clinical trial addresses the question of ...
What are the effects of treatments for unexplained recurrent miscarriage? What are the effects of treatments for recurrent miscarriage caused by antiphospholipid syndrome?
An examination of the symptoms, rupture of blood cells (fibrin production), liver damage, clotting (low serum heparin), high blood pressure (capillary apoptosis), proteinuria (low heparan sulfate (HS) to prevent protein loss), pointed to some obvious treatments and the causes. Infertility is often treated by in vitro fertilization/insemination, supported with aspirin and heparin injections to maintain gestation. These treatments are consistent with high levels of chronic inflammation that block implantation and stimulate labor. Infertility is also associated with antiphospholipid antibodies. A closer look at the antiphospholipid antibodies showed that they were directed against β2-glycoprotein-I. So, I expected the β2-glycoprotein-I protein to be the original target for the antibodies, the initiating antigen, but when I looked up the sequence of that protein, it lacked the expected basic triplet I have found in all other autoantigens and allergens. This meant to me that there was a different ...
Accumulating evidence supports the concept of increased thrombin generation, placental vascular lesions, and inflammation as crucial points in the development of the great obstetrical syndromes [preeclampsia, intrauterine growth restriction (IUGR), preterm labor (PTL), preterm prelabor rupture of membranes (PROM), fetal demise and recurrent abortions]. In light of this, the role of heparins for primary or secondary prevention of these syndromes is becoming more and more apparent, mainly due to the antithrombotic and anti-inflammatory effects of heparins. There is agreement regarding the use of heparin in the prevention of gestational complications in patients with antiphospholipid syndrome, while its use for other obstetrical complications is under debate. In the present review we will describe the physiologic role of heparins on coagulation and inflammation and we will discuss current evidence regarding the use of heparins for the prevention/treatment of obstetrical syndromes ...
Stephan Moll, MD and Damon Houghton, MD write … In patients with antiphospholipid syndrome (APS) who require anticoagulation for the treatment of DVT or PE, warfarin or a low molecular weight heparin have traditionally been used. A question that comes up is whether one of the new oral anticoagulants (DOACs) can be effectively and safely used instead.. It is not known at this point whether DOACs are equally, more or less effective as/than warfarin in patients with APS. Data from clinical trials directly comparing DOACs with warfarin are not yet available. Given the absence of data, no formal recommendations or guidelines exist on this topic. It is an individualized decision between a physician and patient with APS whether to use warfarin or a DOAC for the treatment of DVT or PE.. Published Data. Several case reports and case series of patients with APS treated with a DOAC have been published. All data (from a total of 122 patients) have recently been summarized [1]: Sixteen percent of patients ...
97,. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihile E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M, Euro-Phospholipid Project Group. .Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002; 46: 1019-27 267). Cerca con Google ...
Dr Deepa Jayakody Arachchillage trained in medicine at the North Colombo University in Sri Lanka and trained in haematology at the Newcastle Upon Tyne University Hospitals and University College London (UCL). She was awarded an MD (res) from UCL in July 2015 following successful completion of research related to antiphospholipid syndrome (APS), complement activation and direct acting oral anticoagulants. She has published in many peer reviewed journals and written several book chapters in the field. She has presented in a number of national and international conferences. She has been a co-investigator for several clinical trials and received funding for research projects. Dr Jayakody Arachchillage is a member of the British Society of Haematologists haemostasis and thrombosis task force. She has a specialised clinic for patients with APS at Hammersmith Hospital every Friday.. ...
OBJECTIVES: To put together salient clinical and laboratory manifestations and also to highlight the pathophysiology and principles of management of lupus anticoagulants syndrome. DATA SOURCES: Publications, original and review articles, conference abstracts searched mainly on PubMed indexed for Medline. DATA EXTRACTION: A systematic review to identify studies relating to lupus anticoagulants, clinical, laboratory, pathophysiology and management. Only data relevant to the objectives of the review were extracted. DATA SYNTHESIS: A detailed qualitative assessment was undertaken given the heterogeneity of study types making it not appropriate to pool results across studies. CONCLUSION: It is demonstrated that lupus anticoagulants (LA) are associated with thrombotic events, recurrent foetal loss and female infertility and also occasionally with bleeding due to thrombocytopenia or hypoprothrombinaemia LA interferes with phospholipid dependent laboratory test of coagulation and the test are not ...
Dendritic cells (DCs) regulate both immunity and tolerance. Here we have shown that the ubiquitin editing enzyme A20 (Tnfaip3) determines the activation threshold of DCs, via control of canonical NF-kappa B activation. Tnfaip3(fl)/(fl)Cd11c-cre(+) mice lacking A20 in DCs demonstrated spontaneous proliferation of conventional and double-negative T cells, their conversion to interferon-gamma (IFN-gamma)-producing effector cells, and expansion of plasma cells. They developed ds-DNA antibodies, nephritis, the antiphospholipid syndrome, and lymphosplenomegaly-features of systemic lupus erythematosus-and extramedullary hematopoiesis. A20-deficient DCs were resistant to apoptosis, caused by increased sensitivity to CD40L and RANKL prosurvival signals and upregulation of antiapoptotic proteins Bcl-2 and Bcl-x. They captured injected apoptotic cells more efficiently, resisted the inhibitory effects of apoptotic cells, and induced self-reactive effector lymphocytes. Because genetic polymorphisms in ...
Taatjes, D.J., Quinn, A.S., Wu, X-X., Tsai, H-M., and Rand, J.H. (2014) Repair of nanodefects in a 2-dimensional crystal anticoagulant shield in the antiphospholipid syndrome: Novel molecular strategies assessed by atomic force microscopy. In: NanoCellBiology - Multimodal Imaging in Biology & Medicine (B.P. Jena and D.J. Taatjes, eds.) Pan Stanford Ltd., Singapore, pp. 157-171 ...
Rubovitch V, Edut S, Sarfstein R, Werner H, Pick, C.G. The intricate involvement of the insulin-like growth factor receptor signaling in mild traumatic brain injury in mice. Neurobiol Dis 38:299-303 (2010).. Baratz, R., Rubovitch, V., Frenk, H. and Pick, C.G. The Influence of Alcohol on behavioral recovery following mTBI in mice. J Neurotrauma 27:555-63 (2010).. Defrin R, Gruener, H, Schreiber, S and Pick C.G, Quantitative somatosensory testing of subjects with chronic post traumatic headache: implications on its mechanism. Eur J Pain 14:924-31 (2010).. Katzav, A., Faust-Socher, A., Kvapil, F., Michaelson. D.M., Blank, M., Pick C.G., Shoenfeld, Y., Korczyn, A., Chapman, J. Antiphospholipid syndrome induction exacerbates a transgenic alzheimer disease model on a female background. Neurobiol Ageing 32: 272- 279 (2011).. Zohar O., Lavy R., Zi X., Nelson T.J., Hongpaisan J., Pick C.G., Alkon D.L. PKC activator therapeutic for mild traumatic brain injury in mice. Neurobiol of Dis 41: 329-337 ...
The list of auto immune disorders is given here: Auto-immune diseases include, but are not confined to; Addisons disease, ALS,(Motor Neurone disease) Antiphospholipid syndrome, Arthritis, (Osteo and Rheumatoid Arthritis) Plus the rarer forms of arthritis e.g. This has been an amazing purchase. Scribd ist die weltweit größte soziale Plattform zum Lesen und Veröffentlichen. 41. A real solution to auto immune disorders is to modulate (not suppress) the activity of T cell ratios to normal balance without any side effects. Kalawalla is a very powerful healing herb that can boost, calm and heal your immune system. It has pro-biotic properties, meaning it stimulates the good bacteria in your gut, so is great for your digestion, and its high potassium levels are great for brain, muscle and nerve function. Polypodium leucotomos has many clinical studies that prove that it regulates the CD4/CD8 ratios to their normal values. There are numerous other polypodium leucotomos products on the market, ...
D'Cruz D (February 2009). "Renal manifestations of the antiphospholipid syndrome". Current Rheumatology Reports. 11 (1): 52-60 ... of patients with Cushing's syndrome develop hypertension., which is accompanied by distinct symptoms of the syndrome, such as ... liddle's syndrome (also called pseudoaldosteronism), glucocorticoid remediable aldosteronism Cushing's syndrome - an excessive ... Cushing's syndrome can be caused by taking glucocorticoid drugs, or by tumors that produce cortisol or adrenocorticotropic ...
Glassock, Richard J. (2010). "Other Glomerular Disorders and Antiphospholipid Syndrome". Comprehensive Clinical Nephrology. pp ... This is characteristic of nephrotic syndromes.[citation needed] The clinical presentation of MesPGN is varied, although ...
Hughes Syndrome: Antiphospholipid Syndrome (2nd ed.). Springer. p. 120. ISBN 978-1-85233-873-2. Irvine, Georgeanne (2018). ... The recipient, a 45-year-old woman with Eisenmenger's syndrome, lived for 5 years. A series of combined heart-lung transplant ... Piette, Jean-Charles; Hunt, Beverley J. (2006). "11 Pulmonary Hypertension and Antiphospholipid Antibodies". In Munther A ...
"The catastrophic antiphospholipid syndrome 1996: Acute multi-organ failure associated with antiphospholipid antibodies: A ... Triplett, Douglas A.; Asherson, Ronald A. (2000). "Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS)". ... other than Antiphospholipid syndrome) Treatment for Thrombotic Storm may include lifelong anticoagulation therapy and/or ... "Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three Cases". Seminars in Arthritis and Rheumatism. 37 (6): 366-72 ...
Antiphospholipid antibody syndrome is an important marker for recurrent thrombosis, and often warrants indefinite anticoagulant ... 2008). "Laboratory Evaluation of the Antiphospholipid Syndrome". Hematol Oncol Clin North Am. 22 (1): 19-32. doi:10.1016/j.hoc. ... Kaul M, Erkan D, Sammaritano L, Lockshin MD (July 2007). "Assessment of the 2006 revised antiphospholipid syndrome ... 2006). "International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome ( ...
"Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome". Pharmacotherapy. 23 (5): ... Warfarin is also used in antiphospholipid syndrome. It has been used occasionally after heart attacks (myocardial infarctions ... Less common side effects may include areas of tissue damage and purple toes syndrome. Use is not recommended during pregnancy. ... O'Keeffe, ST; Woods, BO; Breslin, DJ; Tsapatsaris, NP (November 1992). "Blue toe syndrome. Causes and management". Archives of ...
Warkentin TE, Aird WC, Rand JH (2003). "Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome". ... This is also known as Thrombosis with Thrombocytopenia Syndrome or TTS. Ahmed I, Majeed A, Powell R (September 2007). "Heparin ...
Sepsis SLE-associated antiphospholipid syndrome Vitamin deficiency Pancreatitis Malaria Meningococcemia Drug-induced toxicity ( ... "Bilateral Acute Renal Cortical Necrosis in SLE-Associated Antiphospholipid Syndrome". American Journal of Kidney Diseases. 57 ( ... "All-trans retinoic acid syndrome corrected and renal cortical necrosis". Anales de Medicina Interna (Madrid, Spain : 1984). 24 ...
"A lipid associated with the antiphospholipid syndrome regulates endosome structure and function". Nature. 392 (6672): 193-197. ...
1999). "HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta- ... "T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals". ... However, antiphospholipid antibodies bind phospholipids at sites similar to sites bound by anti-coagulants such as PAP1 sites ... Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RF (1993). "Effect of antiphospholipid antibodies on procoagulant activity of ...
She has a specialist clinical and research interest in venous thromboembolism, thromboprophylaxis, antiphospholipid syndrome, ... "Detection of antiphospholipid antibodies based in heparin resistance.", and won the 2011 Research paper of the year at the ...
Later losses appear to occur primarily due to the antiphospholipid syndrome, in spite of treatment with heparin and aspirin. ... All women with lupus, even those without previous history of miscarriage, are recommended to be screened for antiphospholipid ... thrombocytopenia of the HELLP syndrome may appear like that of lupus, and pregnancy-related edema of joints can appear like ...
Morris is the Chair of the medical charity, APS Support UK, for Antiphospholipid syndrome and was patron of Hanover Foundations ...
Patients with anti-cardiolipin antibodies (Antiphospholipid syndrome) can have recurrent thrombotic events even early in their ... Barth syndrome is a rare genetic disorder that was recognised in the 1970s to cause infantile death. It has a mutation in the ... Unlike Barth syndrome, Tangier disease is mainly caused by abnormal enhanced production of CL. Studies show that there are ... Chronic fatigue syndrome is debilitating illness of unknown cause that often follows an acute viral infection. According to one ...
Some immunological reasons that contribute to infertility are reproductive autoimmune failure syndrome, the presence of anti- ... Anti-phospholipid antibodies are targeted toward the phospholipids of the cell membrane. Studies have shown that antibodies ... An individual that presents with reproductive autoimmune failure syndrome has unexplained infertility, endometriosis, and ...
Behcet syndrome, antiphospholipid antibody syndrome or blunt trauma to the back or abdomen. Damage to the endothelial tissue of ... Other less common causes include hypercoagulable state, cancer, kidney transplantation, Behcet syndrome, antiphospholipid ... The incidence of RVT in people with Nephrotic syndrome ranges from 5% to 65%. Nephrotic syndrome is caused by membranous ... newly born infants with blood clotting abnormalities or dehydration and adults with nephrotic syndrome. Nephrotic syndrome, a ...
... or antiphospholipid antibody syndrome) is another common cause. Nearly one-third of patients have a myeloproliferative disorder ... Pylephlebitis Budd-Chiari syndrome DeLeve LD, Valla DC, Garcia-Tsao G (2009). "Vascular disorders of the liver". Hepatology. 49 ... is known as hepatic vein thrombosis or Budd-Chiari syndrome. Portal vein thrombosis causes upper abdominal pain, possibly ...
It may manifest in as high as 56% of lupus patients throughout their life, in contrast to antiphospholipid syndrome which has a ...
... anti-phospholipid antibody syndrome (APS), anti-coagulation, spontaneous, and tumor-related. Acute stress includes stress ...
... antiphospholipid syndrome, juvenile idiopathic arthritis, psoriatic arthritis, juvenile dermatomyositis, idiopathic ... In Sjögren's syndrome, anti-Ro and anti-La antibodies correlate with early onset, increased disease duration, parotid gland ... The presence of both antibodies is found in 30-60% of Sjögren's syndrome, anti-Ro antibodies alone are found in 50-70% of ... Anti-La antibodies are also found in SLE; however, Sjögren's syndrome is normally also present. Anti-Ro antibodies are also ...
... whereas those that occur in antiphospholipid syndrome (associated to lupus for example) are beta-2 glycoprotein dependent, and ...
Uterine incarceration Twin to Twin transfusion syndrome Gestational trophoblastic disease Antiphospholipid antibody syndrome ... A woman may develop an infection, syndrome or complication that is not unique to pregnancy and that may have existed before ... more Seizures Gestational trophoblastic disease Gestational diabetes Hyperemesis gravidarum Pelvic girdle pain HELLP syndrome ...
Antiphospholipid Syndrome Chapter 351: Rheumatoid Arthritis Chapter 358: Inflammatory Myopathies Chapter 352: Acute Rheumatic ... Chronic Fatigue Syndrome Chapter 442: Chronic Fatigue Syndrome Section 5: Psychiatric and Addiction Disorders Chapter 443: ... The Vasculitis Syndromes Chapter 357: Behçet's Syndrome Chapter 359: Relapsing Polychondritis Chapter 360: Sarcoidosis Chapter ... Paraneoplastic Syndromes: Endocrinologic/Hematologic Chapter 90: Paraneoplastic Neurologic Syndromes and Autoimmune ...
... antiphospholipid syndrome, and giant cell arteritis) The medical exam should rule out any underlying causes, such as blood clot ...
... antiphospholipid syndrome In all causes, the mechanism of MAHA is the formation of a fibrin mesh due to increased activation of ... Disseminated intravascular coagulation HELLP syndrome Thrombotic thrombocytopenic purpura Hemolytic uremic syndrome Cancer ... The differential diagnoses are rifampicin or probenecid use, inherited disorders like Gilbert's syndrome and other hemolytic ... In diseases such as hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and ...
Antiphospholipid syndrome Sepsis Giant-cell arteritis (GCA) Hernia Volvulus Sickle-cell disease "Definition of Infarction". ...
... the antiphospholipid syndrome, plasma cell dyscrasias, reactive arthritis, central serous chorioretinitis, open angle glaucoma ... Nocturne G, Pontarini E, Bombardieri M, Mariette X (March 2019). "Lymphomas complicating primary Sjögren's syndrome: from ... Guillain-Barré syndrome, rosacea, psoriasis, chronic urticaria, spot baldness, various autoimmune skin diseases, Henoch- ... blepharitis, diabetes mellitus, the metabolic syndrome, various types of allergies, non-alcoholic fatty liver disease, non- ...
... antiphospholipid syndrome, livedoid vasculitis, vertebrobasilar insufficiency, Behçet's syndrome, idiopathic spontaneous ... 1985). "Crossreactivity of antiphospholipid antibodies". Journal of Clinical & Laboratory Immunology. 16 (1): 1-6. PMID 3981615 ... McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990). "Anti-phospholipid antibodies are directed against a complex antigen ... 1984). "Anticardiolipin antibodies: occurrence in Behçet's syndrome". Ann. Rheum. Dis. 43 (5): 746-748. doi:10.1136/ard.43.5. ...
... can be primary or secondary. Primary antiphospholipid syndrome occurs in the absence of any other ... Antiphospholipid syndrome, or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused ... Islam, Md Asiful (2020). "Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled ... Islam, Md Asiful (2016). "Antiphospholipid antibody-mediated thrombotic mechanisms in antiphospholipid syndrome: Towards ...
Autoimmune thyroiditis Antiphospholipid antibody syndrome The treatment of overlapping connective tissue disorders is mainly ... Sometimes polyangiitis overlap syndrome is used as a synonym for MPA. In gastroenterology, the term overlap syndrome may be ... Wilde AA, Amin AS (May 2018). "Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy". ... An overlap syndrome can be seen whereby a mutation in the SCN5A gene encoding the cardiac sodium channel causes a reduction in ...
... in Waterhouse-Friderichsen syndrome or antiphospholipid syndrome), particular infections (tuberculosis, histoplasmosis, ... such as in the Triple-A or Allgrove syndrome). DAX-1 mutations may cluster in a syndrome with glycerol kinase deficiency with a ... "Autoimmune polyglandular syndrome type 1 , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". ... "Autoimmune polyglandular syndrome type 2 , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". ...
Antiphospholipid syndrom. *Evt. Vascular Instability Syndrome. *Evt. Idiopatisk trombocytopeni (ITP). *Evt. Hæmolytisk anæmi ... and patients with Sjögren's syndrome (mean 203u/ml) (p=0.031) (Figure 1). IL-8 levels were also significantly higher in the ... and patients with Sjögren's syndrome (mean 203u/ml) (p=0.031) (Figure 1). IL-8 levels were also significantly higher in the ...
Antiphospholipid antibody syndrome (APS or APLS). *Behcet syndrome. *Chronic inflammatory demyelinating polyneuropathy ... such as Goodpasture's syndrome,[2] Guillain-Barré syndrome, lupus, myasthenia gravis,[3][4] and thrombotic thrombocytopenic ... "Goodpasture syndrome". U.S. National Library of Medicine. Retrieved 7 April 2013.. ... Other uses are the removal of blood proteins where these are overly abundant and cause hyperviscosity syndrome. ...
adhesion (Bernard-Soulier syndrome) · aggregation (Glanzmann's thrombasthenia) · platelet storage pool deficiency (Hermansky- ... Thrombocytopenic purpura: ITP (Evans syndrome) · TM (TTP). Heparin-induced thrombocytopenia · May-Hegglin anomaly ... membrane: Hereditary spherocytosis(Minkowski-Chauffard syndrome) · Hereditary elliptocytosis (Southeast Asian ovalocytosis) · ... Micro-: Iron deficiency anemia (Plummer-Vinson syndrome). Macro-: Megaloblastic anemia (Pernicious anemia) ...
Antiphospholipid Syndrome Archived 2006-11-17 at the Wayback Machine at SpecialtyLaboratories. Retrieved 27 September 2006. ... Tunpe (1987). "Acute and Chronic Pituitary Failure Resembling Sheehan's Syndrome Following Bites by Russell's Viper in Burma". ... "Acute and chronic pituitary failure resembling Sheehan's syndrome following bites by Russell's viper in Burma". Lancet. 2 (8562 ... "Hypopituitarism following envenoming by Russell's Vipers (Daboia siamensis and D. russelii ) resembling Sheehan's syndrome: ...
"Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome". Pharmacotherapy. 23 (5): ... Raj K, Collins B, Rangarajan S (September 2001). "Purple toe syndrome following anticoagulant therapy". British Journal of ... following acute coronary syndrome". European Heart Journal. 32 (20): 2541-54. doi:10.1093/eurheartj/ehr334. PMC 3295208. PMID ... and purple toe syndrome.[44] Skin necrosis and limb gangrene are most commonly observed on the third to eighth day of therapy.[ ...
Other acquired causes include systemic lupus erythematosus, antiphospholipid syndrome, thyrotoxicosis, polycythaemia rubra vera ... They include the classical Huntington's disease 'mimic' or phenocopy syndromes, called Huntington's disease-like syndrome types ...
"Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome". Pharmacotherapy. 23 (5): ... Purple toe syndromeEdit. See also: Blue toe syndrome. Another rare complication that may occur early during warfarin treatment ... Warfarin is also used in antiphospholipid syndrome. It has been used occasionally after heart attacks (myocardial infarctions ... The common side effect is bleeding.[4] Less common side effects may include areas of tissue damage and purple toes syndrome.[4] ...
... which are associated with antiphospholipid syndrome.[90] Antiphospholipid syndrome is also related to the onset of neural lupus ... Antiphospholipid syndrome. Approximately 20% of people with SLE have clinically significant levels of antiphospholipid ... "Neurological syndromes in systemic lupus erythematosus and their association with antiphospholipid syndrome". Neurol. Neurochir ... Some people, especially those with antiphospholipid syndrome, may have SLE without four of the above criteria, and also SLE may ...
Bernard-Soulier syndrome Unaffected Unaffected Prolonged Decreased or unaffected Factor XII deficiency Unaffected Prolonged ... acute respiratory distress syndrome, multiple organ dysfunction syndrome, major hemorrhage, and venous thromboembolism. ...
Ang isa pang nakikilang uri ng krisis na sickle ang acute chest syndrome na inilalarawan ng trangkaso, kirot sa dibdib, mahirap ...
Antiphospholipid syndrome[8] (such as lupus anticoagulant)[6][7]. *Trauma[6] and minor leg injury[12] ... Budd-Chiari syndrome (thrombosis of the hepatic vein). *Thrombosis of the splanchnic venous system: *Mesenteric vein thrombosis ... Deep vein thrombosis may require thrombolysis if there is a significant risk of post-thrombotic syndrome.[41] Thrombolysis may ...
Antiphospholipid antibody syndrome. altered coagulation. [14] Factor V Leiden defect. altered coagulation. [14] ... Budd-Chiari syndrome[edit]. Main article: Budd-Chiari syndrome. Budd-Chiari syndrome is the blockage of a hepatic vein or of ... paraneoplastic syndrome), by external compression on a blood vessel when a solid tumor is present, or (more rarely) extension ...
... antiphospholipid syndrome,[2]:659 haematological malignancy, and trauma.[3] At first they are usually plum-colored, but then ... antiphospholipid syndrome. Splinter hemorrhages (or haemorrhages) are tiny blood clots that tend to run vertically under the ...
Anti-SSA autoantibodies (Anti-Sjögren's-syndrome-related antigen A, also called anti-Ro, or the combination anti-SSA/Ro or anti ... SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis.[1] Also, ... they are often present in Sjögren's syndrome.[2] [3] Presence of Anti-SSA/Ro in pregnant women with SLE is associated with an ... calpastatin and alpha-fodrin in primary Sjögren's syndrome". Clin. Exp. Immunol. 148 (2): 281-7. doi:10.1111/j.1365-2249.2007. ...
... antiphospholipid syndrome and hemolytic-uremic syndrome. It must be considered a possibility in any pregnant woman beyond 20 ... HELLP Syndrome[edit]. HELLP syndrome is defined as hemolysis (microangiopathic), elevated liver enzymes (liver dysfunction), ... antiphospholipid antibody syndrome, and those with history of pre-eclampsia. *Dietary factors, e.g. calcium supplementation in ... Acutely, pre-eclampsia can be complicated by eclampsia, the development of HELLP syndrome, hemorrhagic or ischemic stroke, ...
... antiphospholipid syndrome). Hyperprothrombinemia can be caused by the G20210A mutation. Thrombin, a potent vasoconstrictor and ...
... and antiphospholipid syndrome". Hematology Am Soc Hematol Educ Program. 2003: 497-519. doi:10.1182/asheducation-2003.1.497. ...
Annese V, Tomietto P, Venturini P, D'Agostini S, Ferraccioli G (2006). "[Migraine in SLE: role of antiphospholipid antibodies ... "Headache, Raynaud's syndrome and serotonin receptor agonists in systemic lupus erythematosus". Lupus 15 (10): 671-4. doi ...
Liver disease, HELLP syndrome, thrombotic thrombocytopenic purpura/Haemolytic uremic syndrome, and malignant hypertension may ... Gando, S (1999). "Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ ... "Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans". Cancer Res. 66 (22): 10643-6. ...
... antiphospholipid syndrome, factor V Leiden, and various other genetic deficiencies or variants).[medical citation needed] ... Mutations in the genes associated with the glycoprotein Ib-IX-V complex are characteristic of Bernard-Soulier syndrome ... Examples of congenital platelet disorders are Glanzmann's thrombasthenia, Bernard-Soulier syndrome (abnormal glycoprotein Ib-IX ... Decreased platelet numbers (thrombocytopenia) is due to insufficient production (e.g., myelodysplastic syndrome or other bone ...
Mucopolysaccharidosis: Hunter syndrome. *Purine-pyrimidine metabolism: Lesch-Nyhan syndrome. *Mineral: Menkes disease/Occipital ...
Alkaptonuria (got onto DYK), Allergy, Alternating hemiplegia of childhood, Anaphylaxis (T), Anemia, Antiphospholipid syndrome, ... Leopard syndrome, Liver disease (T), Liver failure, Long QT syndrome (T), Lung cancer (T), Macrophage activation syndrome (T), ... Guillain-Barré syndrome (T / good article since 12 July 2015), Head and neck cancer (T), Heart failure (T), HELLP syndrome (T ... Obesity hypoventilation syndrome (T / good article since 19 December 2008), Ogilvie syndrome, Orthostatic hypotension (T), ...
Talk:Antidepressant discontinuation syndrome. *Talk:Antiphospholipid syndrome. *Talk:Aphasia. *Talk:Aphasiology. *Talk: ...
Antiphospholipid syndrome[6] (such as lupus anticoagulant)[4][5]. *Trauma[4] and minor leg injury[9] ...
International consensus statement on an update of theclassification criteria for definite antiphospholipid syndrome(APS). ... Evaluation of thrombocytopenia in the acutecoronary syndrome. Curr Opin Hematol 2010; 17(5): 398-404. ... and clinical consequences of acquired thrombocytopeniaafter antithrombotic therapies in patients withacute coronary syndromes: ...
Antiphospholipid syndrome can be primary or secondary. Primary antiphospholipid syndrome occurs in the absence of any other ... Antiphospholipid syndrome, or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused ... Islam, Md Asiful (2020). "Antiphospholipid antibodies and antiphospholipid syndrome in cancer: Uninvited guests in troubled ... Islam, Md Asiful (2016). "Antiphospholipid antibody-mediated thrombotic mechanisms in antiphospholipid syndrome: Towards ...
Can dual antiplatelet therapy effectively prevent thrombosis recurrence in patients with antiphospholipid syndrome? How does it ... Antiphospholipid score and antiphospholipid antibody profiles Total (N=90). Wf (N=13). AP (N=41). Wf + AP (N=21). DAPT (N=15). ... aPL-S: Antiphospholipid score aPL-S are presented as the median (IQR: Interquartile range 25th-75th). aPL: antiphospholipid ... of Dual Antiplatelet Therapy for Preventing Recurrence of Arterial Thrombosis in Patients With Antiphospholipid Syndrome. ...
Can dual antiplatelet therapy effectively prevent thrombosis recurrence in patients with antiphospholipid syndrome? How does it ... Antiphospholipid score and antiphospholipid antibody profiles Total (N=90). Wf (N=13). AP (N=41). Wf + AP (N=21). DAPT (N=15). ... aPL-S: Antiphospholipid score aPL-S are presented as the median (IQR: Interquartile range 25th-75th). aPL: antiphospholipid ... Dual antiplatelet therapy (DAPT) has been shown to be effective for the prevention of acute coronary syndrome or stroke. The ...
Antiphospholipid Syndrome Clinical Research Trial Listings in Hematology Immunology Obstetrics/Gynecology (Womens Health) ... Antiphospholipid Syndrome Clinical Trials. A listing of Antiphospholipid Syndrome medical research trials actively recruiting ... Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome ...
Read our Antiphospholipid antibody syndrome encyclopedia resources online. ... Antiphospholipid antibody syndrome. Antiphospholipid antibody syndrome is a blood-clotting disorder that makes the blood clot ... Antiphospholipid antibody syndrome is caused by antibodies. The body normally makes antibodies that attack a dangerous ... A person who has these antibodies and has had blood clots is said to have antiphospholipid antibody syndrome. ...
... also known as Hughes syndrome - is an autoimmune disorder in which the immune system attacks phospholipids. ... The Latest in Antiphospholipid Syndrome. Antiphospholipid Syndrome. What Is Antiphospholipid Syndrome?. This condition can ... Antiphospholipid syndrome; Genetics Home Reference.. *What Is Antiphospholipid Antibody Syndrome? National Heart, Lung, and ... Antiphospholipid Syndrome Treatment. Antiphospholipid syndrome is treated with medications called blood thinners, which can ...
SNAPS stands for Seronegative Antiphospholipid Antibody Syndrome. SNAPS is defined as Seronegative Antiphospholipid Antibody ... www.acronymfinder.com/Seronegative-Antiphospholipid-Antibody-Syndrome-(SNAPS).html. *Chicago style: Acronym Finder. S.v. "SNAPS ... www.acronymfinder.com/Seronegative-Antiphospholipid-Antibody-Syndrome-(SNAPS).html,SNAPS,/a,. ... www.acronymfinder.com/Seronegative-Antiphospholipid-Antibody-Syndrome-(SNAPS).html ...
Antiphospholipid Syndrome Collaborative Registry (APSCORE) (APSCORE). The safety and scientific validity of this study is the ...
640 patients with antiphospholipid antibody syndrome experience fatigue, Pain, depressed mood, anxious mood, and insomnia and ... Find the most comprehensive real-world symptom and treatment data on antiphospholipid antibody syndrome at PatientsLikeMe. ... and Oxycodone to treat their antiphospholipid antibody syndrome and its symptoms. ... What is antiphospholipid antibody syndrome?. Antiphospholipid syndrome, Hughes syndrome, or antiphospholipid antibody syndrome ...
The Antiphospholipid Syndrome. Edited by R A Asherson, R Cervera, J C Piette, Y Shoenfled. (Pp 330; £127). Boca Raton, USA: CRC ... and gynaecology have been inundated with hundreds of manuscripts regarding the so called antiphospholipid syndrome (APS). ... As a result of the spread of information about the pathogenesis and clinical aspect of antiphospholipid antibodies (APA) in ... it has became apparent that understanding of this syndrome may be of interest to other medical specialties. ...
Antiphospholipid syndrome *What every physician needs to know:*Are you sure your patient has antiphospholipid syndrome? What ... Antiphospholipid syndrome What every physician needs to know:. Antiphospholipid (antibody) syndrome (APS) is a prothrombotic ... Beware of other conditions that can mimic antiphospholipid syndrome:. Other conditions that can mimic antiphospholipid syndrome ... Are you sure your patient has antiphospholipid syndrome? What should you expect to find?. The key symptoms and signs of APS ...
"Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics". Lupus. vol. 19. 2010. pp. 343-346. ... Antiphospholipid Antibody Syndrome (Hughes Disease) ICD-9 286.5. Are You Confident of the Diagnosis?. What you should be alert ... "Antiphospholipid syndrome". Lancet. vol. 376. 2010. pp. 1498-1509. (Along with the first listed reference, a key source for ... "Antiphospholipid syndromes in infectious diseases". Hematol Oncol Clin N Am. vol. 22. 2008. pp. 131-144. ...
This new edition is a comprehensive and updated resource on antiphospholipid syndrome (APS), which is an autoimmune disorder. ... antiphospholipid antibody antiphospholipid syndrome autoimmune disorder obstetric antiphospholipid syndrome pulmonary ... 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report ... 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report ...
Antiphospholipid syndrome is a disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that ... medlineplus.gov/genetics/condition/antiphospholipid-syndrome/ Antiphospholipid syndrome. ... The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. Curr Rheumatol Rep. 2015 Mar; ... 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun ...
Antiphospholipid syndrome (APS) is an autoimmune disorder that involves frequent blood clots (thromboses). When you have this ... Antiphospholipid antibody syndrome. www.nhlbi.nih.gov/health-topics/antiphospholipid-antibody-syndrome. Accessed June 5, 2019. ... 14th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome. ... ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS). In general, you will need treatment with a blood thinner for a long time if you have ...
Overview of antiphospholipid syndrome (APS), an autoimmune disorder associated with risk of inappropriate blood clot formation ... Antiphospholipid antibodies are found in 1% to 5% of the healthy general population. The incidence of antiphospholipid syndrome ... Antiphospholipid syndrome may affect anyone, but women of child-bearing age or those with lupus are more commonly affected. ... Antiphospholipid syndrome (APS) is an autoimmune disorder, meaning that the bodys immune system makes proteins known as ...
Antiphospholipid Syndrome Clinical Research Trial Listings in Hematology Immunology Obstetrics/Gynecology (Womens Health) ... Antiphospholipid Syndrome Clinical Trials. A listing of Antiphospholipid Syndrome medical research trials actively recruiting ...
... the results of antiphospholipid syndrome can be catastrophic for a pregnant woman. Learn about antiphospholipid syndrome ... Antiphospholipid syndrome is also called phospholipid antibody syndrome, cardiolipin antibody syndrome, and Hughes syndrome in ... What is antiphospholipid syndrome? What are antiphospholipid syndrome symptoms and signs?. *What are the causes and risk ... Catastrophic antiphospholipid syndrome (CAPS) is a variant of antiphospholipid syndrome that is characterized by blockage of ...
... Murat Sahin,1 Ayten Oguz,1 Dilek Tuzun,1 Serife Nur Boysan,2 Bülent ... G. P. Mo, P. Germaine, J. Mastoris, and D. H. Henry, "Adrenal hemorrhage associated with antiphospholipid antibody syndrome," ... R. Cervera, J.-C. Piette, J. Font et al., "Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of ... G. Espinosa, E. Santos, R. Cervera et al., "Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic ...
... is a blood-clotting disorder that makes the blood clot ... Antiphospholipid antibody syndrome is caused by antibodies. The body normally makes antibodies that attack a dangerous ... A person who has these antibodies and has had blood clots is said to have antiphospholipid antibody syndrome. ... Antiphospholipid antibodies can be detected with a blood test. When diagnosed, this condition is usually treated with blood- ...
How can blood thinners help with treating antiphospholipid syndrome (APS)?. NEXT QUESTION: What are things I can do to help ... What are treatments for pregnant women with antiphospholipid syndrome (APS)?. ANSWER Pregnant women with APS get injections of ... American College of Rheumatology: "Antiphospholipid Syndrome.". APS Foundation of America: "Antiphospholipid Antibody Syndrome ... American College of Rheumatology: "Antiphospholipid Syndrome.". APS Foundation of America: "Antiphospholipid Antibody Syndrome ...
Purchase Antiphospholipid Syndrome in Systemic Autoimmune Diseases, Volume 12 - 1st Edition. Print Book & E-Book. ISBN ... Pathogenesis of the Antiphospholipid Syndrome; Immunogenetics of the Antiphospholipid Syndrome; Systemic Manifestations of the ... Antiphospholipid Syndrome; Obstetric Manifestations of the Antiphospholipid Syndrome; Antiphospholipid Antibodies and ... Treatment of the Antiphospholipid Syndrome; Difficult situations in the Antiphospholipid Syndrome; ...
Downloading a figure as powerpoint requires a browser with javascript support. Enable javascript and try again For help please contact [email protected] ...
Explore DailyStrengths Antiphospholipid Syndrome support groups and meet others who are facing Antiphospholipid Syndrome ... Antiphospholipid Syndrome Support Group. Antiphospholipid syndrome (or antiphospholipid antibody syndrome) is a disorder of ... Living with Antiphospholipid syndrome can really test your mental resolve and fortitude. I have had several episodes of... READ ... Is there anyone in here with a child who has Antiphospholipid Antibody Syndrome? My daughter was diagnosed at age 10.... READ ...
Thrombosis in the antiphospholipid-antibody syndrome. [N Engl J Med. 1995]. *Answers to the antiphospholipid-antibody syndrome? ... Thrombosis in the antiphospholipid-antibody syndrome. [N Engl J Med. 1995]. *Thrombosis in the antiphospholipid-antibody ... Thrombosis in the antiphospholipid-antibody syndrome. [N Engl J Med. 1995]. *Thrombosis in the antiphospholipid-antibody ... with the antiphospholipid-antibody syndrome and a history of thrombosis were studied retrospectively. The syndrome was primary ...
Click on a [studies] link to search within your current results for studies in that region. Use the back button to return to this list and try another region ...
... macrophage activation syndrome, Stills disease, septic shock and catastrophic antiphospholipid syndrome," BMC Medicine, vol. ... N. Costedoat-Chalumeau, L. Arnaud, D. Saadoun et al., "Catastrophic antiphospholipid syndrome," La Revue de Médecine Interne, ... Plasma Exchange in the Management of Catastrophic Antiphospholipid Syndrome. Dimitri Titeca-Beauport,1,2 Valery Salle,3 Loay ... G. E. Westney and E. N. Harris, "Catastrophic antiphospholipid syndrome in the intensive care unit," Critical Care Clinics, vol ...
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. ...
... syndrome) abbreviated? APLA stands for Antiphospholipid Antibody (syndrome). APLA is defined as Antiphospholipid Antibody ( ... Lupus anticoagulant, antiphospholipid syndrome and cardiac surgery. Antiphospholipid antibody syndrome manifesting as a deep ... Challenges in the diagnosis of the antiphospholipid syndrome. Recognition and management of patients with antiphospholipid ... Antiphospholipid syndrome and acute HIV infection. Mesenteric and portal venous obstruction associated with primary ...
Syndrome. Antiphospholipid Syndrome. Disease. Pathologic Processes. Autoimmune Diseases. Immune System Diseases. Vitamins. ... Antiphospholipid syndrome. Antiphospholipid antibodies. Vitamin-K antagonists. International normalized ratio. Chromogenic ... To Assess the Influence of Antiphospholipid Antibodies on INR Test Results in Patients with the Antiphospholipid Syndrome ... Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome. The safety and scientific validity of this study is the ...
Methods To identify new loci conferring susceptibility to thrombotic antiphospholipid syndrome, a two-stage genotyping strategy ... exhibited the strongest association with thrombotic antiphospholipid syndrome (p-value = 5,9 × 10−4 OR 95% CI 1.84 (1.32-2.55 ... Background Thrombotic antiphospholipid syndrome is defined as a complex form of thrombophilia that is developed by a fraction ... of antiphospholipid antibody (aPLA) carriers. Little is known about the genetic risk factors involved in thrombosis development ...
Antiphospholipid Syndrome (APS) is characterized by the presence of arterial or venous thrombosis and anti-phospholipid ... Antiphospholipid Syndrome (APS) is characterized by the presence of arterial or venous thrombosis and anti-phospholipid ... Antiphospholipid Syndrome (APS) is characterized by the presence of arterial or venous thrombosis and anti-phospholipid ... Keywords: Systemic Lupus Erythematosus, Antiphospholipid Syndrome, Autoimmunity Important Note: All contributions to this ...
Update on Antiphospholipid Antibody Syndrome Management , IntechOpen, Published on: 2012-04-20. Authors: Rocco Manganelli, ... Update on Antiphospholipid Antibody Syndrome Management. By Rocco Manganelli, Salvatore Iannaccone, Serena Manganelli and Mario ... Medicine » Immunology, Allergology and Rheumatology » Antiphospholipid Syndrome, book edited by Alena Bulikova, ISBN 978-953- ...
  • Antiphospholipid syndrome, or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by antiphospholipid antibodies. (wikipedia.org)
  • Antiphospholipid antibody syndrome is a blood-clotting disorder that makes the blood clot too easily. (northshore.org)
  • Antiphospholipid antibody syndrome is caused by antibodies. (northshore.org)
  • A person who has these antibodies and has had blood clots is said to have antiphospholipid antibody syndrome. (northshore.org)
  • Antiphospholipid syndrome, Hughes syndrome, or antiphospholipid antibody syndrome is a disorder that causes blood clots (thrombosis) to form in the arteries, veins, and vital organs. (patientslikeme.com)
  • Data from patients with antiphospholipid antibody syndrome, who reported starting treatments within the last 5 years. (patientslikeme.com)
  • There are issues with standardizing antiphospholipid antibody testing that are ongoing. (clinicaladvisor.com)
  • Deep brain reversible encephalopathy: association with secondary antiphospholipid antibody syndrome. (radiopaedia.org)
  • Abdominal thrombotic and ischemic manifestations of the antiphospholipid antibody syndrome: CT findings in 42 patients. (radiopaedia.org)
  • The antiphospholipid antibody tests considered in this analysis are lupus anticoagulant, the anticardiolipin antibody, and the antibeta-2 glycoprotein 1 antibody. (endocrinologyadvisor.com)
  • In patients with systemic lupus, the presence of an antiphospholipid antibody increases the incidence of thromboembolic events 2- to 3-fold. (endocrinologyadvisor.com)
  • In general, the more antiphospholipid antibody tests that are positive and the greater the positivity of the test, the greater the risk is for thrombosis and for pregnancy complications. (endocrinologyadvisor.com)
  • Holtan, SG, Knox, SK & Tefferi, A 2006, ' Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia [9] ', Journal of Thrombosis and Haemostasis , vol. 4, no. 7, pp. 1632-1634. (elsevier.com)
  • The antiphospholipid syndrome is an antibody-mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events. (ashpublications.org)
  • The antiphospholipid syndrome is an antibody-mediated prothrombotic disorder, similar to heparin-induced thrombocytopenia. (ashpublications.org)
  • Consequently, the diagnosis of a patient with the antiphospholipid syndrome requires the presence of specific clinical manifestations as well as the identification of an antiphospholipid antibody ( Table 1 ). (ashpublications.org)
  • Laboratory criteria for the syndrome consist of elevated anticardiolipin antibody levels and/or a lupus anticoagulant detected in the blood on two or more occasions, at least 6 weeks apart. (ashpublications.org)
  • Antiphospholipid Antibody Syndrome (APS) is a highly prevalent cause of antibody-mediated thrombosis manifesting in venous thrombosis (DVT and PE), arterial thrombosis (most commonly stroke), and pregnancy complications. (openurologyandnephrologyjournal.com)
  • Since thrombosis and pregnancy loss are common in the general population, and antiphospholipid antibodies (aPL) occurs in a small percentage of the healthy public, it is important to demonstrate antibody persistence in patients who have the proper clinical indications in order to avoid misdiagnosis. (openurologyandnephrologyjournal.com)
  • While the child also carried one prothrombotic allele of factor V (Leiden allele), which may have contributed to the risk of thromboembolic disease, the serological analysis represents unequivocal evidence of de novo neonatal primary phospholipid antibody syndrome. (elsevier.com)
  • Women who have clotting disorders like antiphospholipd syndrome, lupus anticoagulant or anticardiolipin antibody syndrome are at risk for recurrent pregnancy loss in the second trimester. (pinterest.co.uk)
  • We report the first case of antiphospholipid antibody syndrome presenting as bioprosthetic mitral valve thrombosis, 15 months after valve replacement, and successfully treated with thrombolytic therapy. (elsevier.com)
  • We concluded there are few controlled clinical trials that have included a heterogeneous group of APS patients who exhibit many different forms of the disease and antiphospholipid antibody test results. (healthcanal.com)
  • Primary antiphospholipid syndrome occurs in the absence of any other related disease. (wikipedia.org)
  • The disorder can be primary ( primary antiphospholipid syndrome ) or secondary (i.e. associated with systemic lupus erythematosus ). (radiopaedia.org)
  • Publications] Atsumi T: 'Correlation between β2-glycoprotein I valine/leucine 247 polymorphism and anti β2-glycoprotein I antibodies in patients with the primary antiphospholipid syndrome'Rheumatology. (nii.ac.jp)
  • Primary antiphospholipid syndrome refers to patients with the syndrome who do not have any other rheumatologic or autoimmune conditions, whereas secondary antiphospholipid syndrome refers to patients who also have systemic lupus erythematosus (SLE) or other conditions. (ashpublications.org)
  • Myocardial infarction in young patients without coronary atherosclerosis: assume primary antiphospholipid syndrome until proved otherwise. (ox.ac.uk)
  • Risk factors for developing antiphospholipid syndrome include: Genetic Markers: HLA-DR4, HLA-DR7, and HLA-DRw53 Race: Blacks, Hispanics, Asians, and Native Americans[citation needed] Antiphospholipid syndrome is an autoimmune disease, in which "antiphospholipid antibodies" (anticardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes. (wikipedia.org)
  • Antiphospholipid syndrome is an autoimmune disease , in which "antiphospholipid antibodies" (anticardiolipin antibodies and lupus anticoagulant) react against proteins that bind to anionic phospholipids on plasma membranes . (wikipedia.org)
  • The classical clinical picture of the antiphospholipid syndrome (APS) is characterized by venous and arterial thromboses, fetal losses and thrombocytopenia, in the presence of antiphospholipid antibodies (aPL), namely lupus anticoagulant (LA), anticardiolipin antibodies (aCL), or antibodies to the protein "cofactor" b2 glycoprotein I. Single vessel involvement or multiple vascular occlusions may give rise to a wide variety of presentations. (springer.com)
  • Antiphospholipid antibodies include anticardiolipin antibodies, the lupus anticoagulant, and antibeta-2 glycoprotein 1 antibodies. (endocrinologyadvisor.com)
  • The laboratory criteria are the presence of an elevated concentration of antiphospholipid antibodies, which includes a positive test for the lupus anticoagulant, present on 2 or more occasions at least 12 weeks apart. (endocrinologyadvisor.com)
  • Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. (regionh.dk)
  • Positive lupus anticoagulant, anticardiolipin antibodies, and anti-beta2-glycoprotein I antibodies are seen but are not specific for antiphospholipid syndrome if considered in isolation (see diagnostic criteria below) 6 . (radiopaedia.org)
  • The 14th International Congress on Antiphospholipid Antibodies Task Force criteria for identifying APS requires testing for cardiolipin antibodies, lupus anticoagulant, and beta-2 glycoprotein antibodies when one of two clinical problems exist, blood clots (thrombosis) or pregnancy morbidity. (labcorp.com)
  • The syndrome is identified by persistent abnormalities of laboratory tests for antibodies against these phospholipid-protein cofactor complexes, detected by immunoassays and by coagulation assays (also known as "lupus anticoagulant assays") that, paradoxically, report the inhibition of phospholipid-dependent coagulation reactions. (mhmedical.com)
  • Lupus anticoagulant antibodies are one of the markers for antiphospholipid syndrome, a condition tied to recurrent pregnancy loss. (pinterest.co.uk)
  • Antiphospholipid Syndrome (APS) is an autoimmune disorder characterized by thrombosis and/or pregnancy morbidity in presence of persistent antiphospholipid antibodies such as lupus anticoagulant (LA), isotype IgG and/or IgM for anti-beta-2-glycoprotein I (aB2GPI) and anti-cardiolipin antibodies (aCL) ( 1 - 4 ). (frontiersin.org)
  • Micrograph showing an advanced thrombotic microangiopathy , as may be seen in ALPA syndrome. (wikipedia.org)
  • Antiphospholipid syndrome (APS) is characterized by thromboses in the larger arteries and veins and thrombotic microangiopathy. (svarlifescience.com)
  • For patients with thrombotic complications, venous thrombosis is encountered most commonly, occurring in the lower extremities in up to 50% of patients with the syndrome. (ashpublications.org)
  • 2 Other prominent clinical manifestations that are frequently seen in these patients, but which are considered non-diagnostic for the antiphospholipid syndrome, include cardiac valvular abnormalities, livedo reticularis, and a variety of non-thrombotic neurologic manifestations. (ashpublications.org)
  • Antiphospholipid antibodies from patients with the syndrome have been shown to play a direct role in the development of thrombotic manifestations in experimental animal models. (ashpublications.org)
  • Antiphospholipid antibodies are also associated with low platelet counts (thrombocytopenia) and with the risk of recurrent miscarriages (especially in the second and third trimester), premature labor, and pre-eclampsia. (labcorp.com)
  • Antiphospholipid syndrome (APS), also called Hughes syndrome, is a recognized group of signs and symptoms that includes the formation of blood clots, miscarriages, platelet deficiency (thrombocytopenia), and the presence of one or more antiphospholipid antibodies. (labcorp.com)
  • Abnormalities that have been reported in association with the syndrome include virtually all other autoimmune disorders, immune thrombocytopenia, acquired platelet function abnormalities, hypoprothrombinemia, acquired inhibitors of coagulation factors, livedo reticularis, heart valve abnormalities, atherosclerosis, pulmonary hypertension, and migraine. (mhmedical.com)
  • Taking blood thinners requires extreme caution during pregnancy, but these drugs can help women with antiphospholipid syndrome successfully carry a baby. (everydayhealth.com)
  • Treatment with hydroxychloroquine may reduce pregnancy risks and increase gestational duration in women with antiphospholipid syndrome, according to data presented at the European League Against Rheumatism Annual European Congress of Rheumatology. (lupus-support.org)
  • Researchers conducted an observational study of 170 pregnancies in 96 women with antiphospholipid syndrome (aPL). (lupus-support.org)
  • Gestational Age Above 12 Weeks Predicts Favorable Obstetric Outcome in Women with Antiphospholipid Syndrome (APS) Associated with First-Trimester Recurrent Pregnancy Loss (RPL) Treated with Enoxaparin and Low Dose Aspirin. (ashpublications.org)
  • The current classification criteria for antiphospholipid syndrome include both laboratory criteria and clinical criteria. (endocrinologyadvisor.com)
  • Although anti-β 2 -glycoprotein I antibodies are currently not included in the diagnostic laboratory criteria for antiphospholipid syndrome, many investigators consider the presence of these autoantibodies to be more specific for the syndrome. (ashpublications.org)
  • Clinically important antiphospholipid antibodies (those that arise as a result of the autoimmune process) are associated with thrombosis and vascular disease. (wikipedia.org)
  • Patients with definite APS therefore have persistent presence of antiphospholipid antibodies on two or more occasions, and objectively confirmed vascular thrombosis, or pregnancy morbidity. (clinicaladvisor.com)
  • It is usually defined as the clinical complex of vascular occlusion and ischaemic events occurring in patients who have circulating antiphospholipid antibodies. (radiopaedia.org)
  • The antiphospholipid (aPL) syndrome (APS) is an acquired thrombophilic disorder in which patients have vascular thrombosis and/or pregnancy complications attributable to placental insufficiency, accompanied by laboratory evidence for the presence of antiphospholipid antibodies in blood. (mhmedical.com)
  • Patients with definite APS must have documented persistent presence of antiphospholipid antibodies, in addition to clinical manifestations (thrombosis and/or pregnancy morbidity). (clinicaladvisor.com)
  • Antiphospholipid syndrome (APS) is an acquired autoimmune disorder defined by the presence of both clinical (thromboembolic events or pregnancy morbidity) and laboratory (antiphospholipid antibodies, aPL) manifestations. (frontiersin.org)
  • Antiphospholipid syndrome can be primary or secondary. (wikipedia.org)
  • The syndrome can be divided into primary (no underlying disease state) and secondary (in association with an underlying disease state) forms. (wikipedia.org)
  • In general, the clinical manifestations of the antiphospholipid syndrome are similar for primary and secondary forms of the disease. (ashpublications.org)
  • There is a subset of APS known as catastrophic APS (CAPS) characterized by presence of antiphospholipid antibodies in patients developing small vessel occlusions affecting multiple organ systems over a period of 7 days or less. (clinicaladvisor.com)
  • The objective of this study was to highlight the need for investigation of antiphospholipid (aPL) antibodies in patients presenting with myocardial infarction (MI) and normal coronary arteries at angiography. (ox.ac.uk)
  • Nonthrombotic manifestations of antiphospholipid syndrome include a host of cardiovascular diseases, neurologic disorders, hematologic disorders, renal dysfunction, and cutaneous changes. (endocrinologyadvisor.com)
  • Management of organ-specific manifestations of antiphospholipid syndrome are beyond the scope of this general article. (radiopaedia.org)
  • Analysis of T cell epitopes in the patients with the antiphospholipid syndrome. (nii.ac.jp)
  • During the past 12 years both clinicians and researchers involved in rheumatology, haematology, clinical immunology, and gynaecology have been inundated with hundreds of manuscripts regarding the so called antiphospholipid syndrome (APS). (bmj.com)
  • New York - Motivated by the lack of treatment options for patients with antiphospholipid syndrome (APS), rheumatology researchers convened an international committee to address the problem directly. (healthcanal.com)
  • Not everyone with the antibodies that cause antiphospholipid syndrome will experience problems with blood clotting. (everydayhealth.com)
  • Publications] Tsutsumi A: 'Reflex sympathetic dystrophy in a patient with the antiphospholipid syndrome'Lupus. (nii.ac.jp)
  • Patients who develop multiple thromboses over days, despite appropriate anticoagulation, and experience adrenal failure, myocardial infarction, stroke, or liver failure may be suffering from catastrophic antiphospholipid syndrome. (endocrinologyadvisor.com)
  • Cardiolipin antibodies (IgG, IgM, and sometimes IgA) are frequently ordered since they are the most common antiphospholipid antibodies. (labcorp.com)
  • As a result of the spread of information about the pathogenesis and clinical aspect of antiphospholipid antibodies (APA) in humans, 'non-professional APA readers' have been often puzzled by APA characterisation, criteria for APS definition, reliability of assays for APA detection, and APS management. (bmj.com)
  • Diagnosis is made using the revised Sapporo criteria, in which patients need to meet at least one clinical and at least one laboratory criteria to fulfill the diagnosis of antiphospholipid syndrome 7 . (radiopaedia.org)
  • The diagnosis of definite APS requires both clinical and laboratory criterion as established by the working group of the International Congress on Antiphospholipid Antibodies (based on expert opinion). (openurologyandnephrologyjournal.com)
  • Patients have circulating antiphospholipid antibodies cross-react with cell membrane phospholipids. (radiopaedia.org)
  • Antiphospholipid antibodies are a group of immune proteins (antibodies) that the body mistakenly produces against itself in an autoimmune response to phospholipids. (labcorp.com)
  • The presence of antiphospholipid antibodies (aPL) in the absence of blood clots or pregnancy-related complications does not indicate APS (see below for the diagnosis of APS). (wikipedia.org)
  • Symptoms of antiphospholipid syndrome depend on where the blood clots form (in arteries or in veins). (everydayhealth.com)
  • Antiphospholipid syndrome is treated with medications called blood thinners, which can stop more blood clots from forming. (everydayhealth.com)